http://jnci.oxfordjournals.org/content/101/4/256.full
<!DOCTYPE html
  PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd">
<html
      xmlns="http://www.w3.org/1999/xhtml"
      xml:lang="en"
      lang="en">
   <head>
      <meta http-equiv="Content-Type" content="text/html; charset=UTF-8" />
      <title>Aspirin for the Chemoprevention of Colorectal Adenomas: Meta-analysis of the Randomized Trials </title>
      <meta name="googlebot" content="NOODP" />
      <meta name="HW.ad-path" content="/cgi/content/full/101/4/256" />
      <meta content="/jnci/101/4/256.atom" name="HW.identifier" />
      <meta name="DC.Format" content="text/html" />
      <meta name="DC.Language" content="en" />
      <meta content="Aspirin for the Chemoprevention of Colorectal Adenomas: Meta-analysis of the Randomized Trials"
            name="DC.Title" />
      <meta content="10.1093/jnci/djn485" name="DC.Identifier" />
      <meta content="2009-02-18" name="DC.Date" />
      <meta content="Oxford University Press" name="DC.Publisher" />
      <meta content="Bernard F. Cole" name="DC.Contributor" />
      <meta content="Richard F. Logan" name="DC.Contributor" />
      <meta content="Susan Halabi" name="DC.Contributor" />
      <meta content="Robert Benamouzig" name="DC.Contributor" />
      <meta content="Robert S. Sandler" name="DC.Contributor" />
      <meta content="Matthew J. Grainge" name="DC.Contributor" />
      <meta content="Stanislas Chaussade" name="DC.Contributor" />
      <meta content="John A. Baron" name="DC.Contributor" />
      <meta content="Journal of the National Cancer Institute"
            name="citation_journal_title" />
      <meta content="JNCI J Natl Cancer Inst" name="citation_journal_abbrev" />
      <meta content="0027-8874" name="citation_issn" />
      <meta content="1460-2105" name="citation_issn" />
      <meta name="citation_author" content="Bernard F. Cole" />
      <meta name="citation_author" content="Richard F. Logan" />
      <meta name="citation_author" content="Susan Halabi" />
      <meta name="citation_author" content="Robert Benamouzig" />
      <meta name="citation_author" content="Robert S. Sandler" />
      <meta name="citation_author" content="Matthew J. Grainge" />
      <meta name="citation_author" content="Stanislas Chaussade" />
      <meta name="citation_author" content="John A. Baron" />
      <meta content="Aspirin for the Chemoprevention of Colorectal Adenomas: Meta-analysis of the Randomized Trials"
            name="citation_title" />
      <meta content="101" name="citation_volume" />
      <meta content="4" name="citation_issue" />
      <meta content="256" name="citation_firstpage" />
      <meta content="266" name="citation_lastpage" />
      <meta content="101/4/256" name="citation_id" />
      <meta content="101/4/256" name="citation_id_from_sass_path" />
      <meta content="jnci;101/4/256" name="citation_mjid" />
      <meta content="10.1093/jnci/djn485" name="citation_doi" />
      <meta content="http://jnci.oxfordjournals.org/content/101/4/256.abstract"
            name="citation_abstract_html_url" />
      <meta content="http://jnci.oxfordjournals.org/content/101/4/256.full"
            name="citation_fulltext_html_url" />
      <meta content="http://jnci.oxfordjournals.org/content/101/4/256.full.pdf"
            name="citation_pdf_url" />
      <meta content="/content/101/4.cover.gif" name="issue_cover_image" />
      <meta content="http://jnci.oxfordjournals.org/content/101/4/256"
            name="citation_public_url" />
      <meta content="19211452" name="citation_pmid" />
      <meta name="citation_section" content="Article" />
      <meta name="robots" content="noarchive,nofollow" />
      <meta name="googlebot" content="noarchive" />
      <link href="/content/101/4/248.short" rel="prev" />
      <link href="/content/101/4/267.short" rel="next" />
      <link rel="stylesheet" type="text/css" media="all" href="/shared/css/hw-global.css" />
      <link rel="stylesheet" type="text/css" media="print" href="/shared/css/hw-print.css" />
      <link rel="stylesheet" type="text/css" media="all"
            href="/local/css/hw-local-global.css" />
      <link rel="stylesheet" type="text/css" media="all"
            href="/publisher/css/hw-publisher-global.css" />
      <link rel="stylesheet" type="text/css" media="all"
            href="/publisher/css/hw-publisher-ac.css" />
      <link rel="stylesheet" type="text/css" media="all"
            href="/shared/css/hw-page-content.css" />
      <link rel="stylesheet" type="text/css" media="all"
            href="/shared/css/jquery.fancybox-1.3.4.css" />
      <link rel="stylesheet" type="text/css" media="all"
            href="/shared/css/hw-global-colexpand.css" />
      <link rel="stylesheet" type="text/css" media="all"
            href="/publisher/css/hw-publisher-page-content.css" /><script type="text/javascript" id="session-d29561385e1">var callbackToken='53719C7814F367A';</script><script type="text/javascript" id="session-d29561385e3">
                      var subCode='oupjournal_sub';
                    </script><script type="text/javascript">
            var gAuthTimeStamp = '2015-10-27T12:16:31.618-07:00';
            var gSessionId = '5uJRtRsYbHcNISjUxjykpA';
            var gAuthzRequired = 'false';
            var gAuthnMethods1 = 'ip ip';
            var gAuthnMethods2 = 'ip,ip';
            var gAuthnIPs = '18.189.59.169,18.189.59.169';
            var gAuthnIndividuals = '';
            var gAuthnInstitutions = '10005282,10072538,10328193,100274300,10082403,05094000,10093227,153074108,10080507,21879000,10095822,10081742,10082405,10004595,10019502,10082401,07635000,10082404,06602000';
            </script><script type="text/javascript" src="/shared/js/jquery-min.js"></script><script type="text/javascript" src="/shared/js/fingerprint.js"></script><script type="text/javascript" src="/shared/js/hw-shared.js"></script><script type="text/javascript" src="/publisher/js/hw-publisher-site.js"></script><script type="text/javascript" src="/local/js/local-js-vars.js"></script><script type="text/javascript" src="/shared/js/pages/hw-content.js"></script><script type="text/javascript" src="/shared/js/fancybox/jquery.fancybox-1.3.4.js"></script><script type="text/javascript" src="/shared/js/fancybox/jquery.easing-1.3.pack.js"></script><script type="text/javascript"
              src="/shared/js/fancybox/jquery.mousewheel-3.0.4.pack.js"></script><script type="text/javascript" src="/shared/js/util/content.jquery.addVariantLink.js"></script><script type="text/javascript" src="/shared/js/util/hw-col-expand.js"></script><script type="text/javascript" src="/publisher/js/hw-publisher-modalwin-vars.js"></script><script type="text/javascript"
              src="/publisher/js/hw-publisher-article-dynamic-elements.js"></script><script type="text/javascript" src="/publisher/js/hw-publisher-content.js"></script><script type="text/javascript" src="/shared/js/util/hw-mathjax.js"></script><script type="text/x-mathjax-config">
          MathJax.Hub.Config({
              tex2jax: {
                inlineMath: [["$","$"],["\\(","\\)"]],
                processClass: "tex2jax_process|mathjax"
              }
            });
          MathJax.Hub.Queue(function() {
            gColTempResize = true;
            fixColHeights(1);
            gColTempResize = false;
          });
       </script><script type="text/javascript"
              src="http://cdn.mathjax.org/mathjax/latest/MathJax.js?config=TeX-AMS-MML_HTMLorMML"></script><script type="text/javascript">
	    
	    
	    
	    var siqDOI = encodeURIComponent("10.1093/jnci/djn485");
	    var siqIsOpenAccess = encodeURIComponent("");
	    var siqPubDate = encodeURIComponent("20090218");

	    if (siqDOI.length == 0) {
	        siqDOI = "UNKNOWN";
	    }
	    
	    
		
		
	    if (gAuthnIndividuals.length != 0) {
		if (gAuthnInstitutions.length != 0) {
		    authnEntity = encodeURIComponent(gAuthnIndividuals
		        + ',' + gAuthnInstitutions);
		} else {
		    authnEntity = encodeURIComponent(gAuthnIndividuals);
		}
	    } else {
	        authnEntity = encodeURIComponent(gAuthnInstitutions);
	    }

	    var commonString =
		'authSessionId=' + gSessionId + String.fromCharCode(0x26)
		+ 'authzRequired=' + gAuthzRequired + String.fromCharCode(0x26)
		+ 'authentication_method=' + encodeURIComponent(gAuthnMethods2) + String.fromCharCode(0x26)
		+ 'authnIPs=' + gAuthnIPs + String.fromCharCode(0x26)
		+ 'authnInstitutions=' + authnEntity;

		
		
		
		

	    var gPageId = "pageid-content";
	    var gVariant = "full-text";

	    
		// Not completely done
		var eventType = "full-text";
		var accessType;
		if (siqIsOpenAccess == 'true') {
		    accessType = 'SOA';
		} else {
		    accessType = 'subscription';
		}
		    
		var NTPT_PGEXTRA =
		    commonString + String.fromCharCode(0x26)
		    + 'event_type=' + eventType + String.fromCharCode(0x26)
		    + 'publication_date=' + siqPubDate + String.fromCharCode(0x26)
		    + 'access_type=' + accessType + String.fromCharCode(0x26)
		    + 'doi=' + siqDOI ;
		    
		

	    // alert("NTPT_PGEXTRA is " + NTPT_PGEXTRA);
	</script><link rel="stylesheet" type="text/css" media="all" href="/resource/css/hw20.css" />
      <link rel="stylesheet" type="text/css" media="all"
            href="/resource/css/h20-oup-header.css" />
      <link rel="stylesheet" type="text/css" media="all"
            href="/resource/css/h20-oup-footer.css" />
      <link rel="stylesheet" type="text/css" media="all"
            href="/resource/css/h20-oup-sidebars.css" />
      <link type="text/css" media="all" rel="stylesheet" href="/site/resource/jnci_h20.css" />
      <link rel="stylesheet" type="text/css" href="/resource/css/print.css" media="print" /><script type="text/javascript" src="/resource/js/main.js"></script><link rel="stylesheet" type="text/css" media="all"
            href="http://oi-underbar.ifactory.com/underbar/css/pf_oiunderbar.css" />
      <link rel="stylesheet" type="text/css" media="screen"
            href="http://gab.cookie.oup.com/aws-cookie/jquery.fancybox-1.3.4_1.css" /><script type="text/javascript" src="/resource/js/oup_ad_size.js"></script></head>
   <body class="general_page journal jnci">
      <div class="hw-gen-page pagetype-content hw-pub-id-article" id="pageid-content"
           itemscope="itemscope"
           itemtype="http://schema.org/ScholarlyArticle">
         <noscript>
            <p>We use cookies to enhance your experience on our website. By continuing to use our website, you are agreeing to our use of
               cookies. You can change your cookie settings at any time. <a href="http://global.oup.com/cookiepolicy/">Find out more</a></p>
         </noscript>
         
         
         <p class="hide">
            <a href="#content">Skip Navigation</a>
            
         </p>
         
         
         <div id="secondary_nav">
            <strong id="page_logo" title="Oxford Journals"><a href="http://www.oxfordjournals.org/"><span>Oxford Journals</span></a></strong>
            
            <ul>
               <li id="nav_contact_us" title="Contact Us"><a href="http://www.oxfordjournals.org/contact_us.html"><span>Contact Us</span></a></li>
               <li id="nav_my_basket" title="My Basket"><a href="https://secure.oxfordjournals.org/basket.html"><span>My Basket</span></a></li>
               <li id="nav_my_account" title="My Account"><a href="http://services.oxfordjournals.org/cgi/tslogin?url=http://www.oxfordjournals.org/service/Register"><span>My 
                        
                        Account</span></a></li>
            </ul>
            
         </div>
         
         
         <div id="header">
            
            <h1 id="page_title" title="JNCI J Natl Cancer Inst"><a href="/"><span>
                     JNCI J Natl Cancer Inst
                     </span></a></h1>
            
         </div>
         
         
         <div id="primary_nav">
            
            <ul>
               <li id="nav_about_this_journal" title="About This Journal">
                  <a href="http://www.oxfordjournals.org/jnci/about.html">
                     
                     <span>About This Journal</span>
                     </a>
                  
               </li>
               <li id="nav_contact_this_journal" title="Contact This Journal"><a href="/cgi/feedback/"><span>Contact This Journal</span></a></li>
               <li id="nav_subscriptions" title="Subscriptions">
                  <a href="http://www.oxfordjournals.org/jnci/access_purchase/buy_online.html">
                     
                     <span>Subscriptions</span>
                     </a>
                  
               </li>
               <li id="nav_current_issue" title="Current"><a href="/content/current"><span>View Current Issue (Volume 107 Issue 10 October 2015)</span></a></li>
               <li id="nav_archive" title="Archive"><a href="/content/by/year"><span>Archive</span></a></li>
               <li id="nav_search" title="Search"><a href="/search"><span>Search</span></a></li>
            </ul>
            
         </div>
         
         
         <div id="user_nav">
            
            <div class="header-ac-elements">
               
               <div id="authstring">
                  
                  <ul>
                     <li class="subscr-ref">Institution:  MIT Libraries</li>
                     <li class="no-left-border">
                        <a href="/login?uri=http%3A%2F%2Fjnci.oxfordjournals.org%2Fcontent%2F101%2F4%2F256.full">
                           Sign In as Personal Subscriber
                           </a>
                        
                     </li>
                  </ul>           
                  
               </div>   
               
            </div>
            
         </div>
         
         
         <ul id="site-breadcrumbs">
            <li class="first"><a href="http://services.oxfordjournals.org/cgi/tslogin?url=http%3A%2F%2Fwww.oxfordjournals.org">Oxford Journals</a></li>
            <li><span class="breadcrumb_subjects"><a href="http://www.oxfordjournals.org/subject/medicine/"
                     class="breadcrumb_subject">Medicine &amp; Health</a></span></li>
            <li><a href="/">JNCI J Natl Cancer Inst</a></li>
            <li><a href="/content/101/4.toc">
                  <span xmlns="" class="volume-value">Volume 101</span>
                  <span xmlns="" class="issue-value"> Issue 4</span></a></li>
            <li>Pp. <span class="slug-pages">
                  256-266.
                  </span></li>
         </ul>
         
         
         
         
         <div id="oas_top" class="ad_hidden">
            <iframe id="id_advertframe_top"
                    src="/resource/htmlfiles/advert.html?p=Top&amp;u=jnci.oxfordjournals.org/content/101/4/256.full"
                    width="0"
                    height="0"
                    frameborder="0"
                    scrolling="no"
                    class="resize_ad"></iframe>
            
         </div>
         
         
         <a name="content"></a>
         
         
         <div id="h20_page"></div>
         
         <div id="content-block">
            <div class="article fulltext-view" itemprop="articleBody"><span class="highwire-journal-article-marker-start"></span><h1 id="article-title-1" itemprop="headline">Aspirin for the Chemoprevention of Colorectal Adenomas: Meta-analysis of the Randomized Trials</h1>
               <div class="contributors">
                  <ol class="contributor-list" id="contrib-group-1">
                     <li class="contributor" id="contrib-1" itemprop="author" itemscope="itemscope"
                         itemtype="http://schema.org/Person"><span class="name" itemprop="name"><a class="name-search"
                              href="/search?author1=Bernard+F.+Cole&amp;sortspec=date&amp;submit=Submit">Bernard F. Cole</a></span>, 
                     </li>
                     <li class="contributor" id="contrib-2" itemprop="author" itemscope="itemscope"
                         itemtype="http://schema.org/Person"><span class="name" itemprop="name"><a class="name-search"
                              href="/search?author1=Richard+F.+Logan&amp;sortspec=date&amp;submit=Submit">Richard F. Logan</a></span>, 
                     </li>
                     <li class="contributor" id="contrib-3" itemprop="author" itemscope="itemscope"
                         itemtype="http://schema.org/Person"><span class="name" itemprop="name"><a class="name-search"
                              href="/search?author1=Susan+Halabi&amp;sortspec=date&amp;submit=Submit">Susan Halabi</a></span>, 
                     </li>
                     <li class="contributor" id="contrib-4" itemprop="author" itemscope="itemscope"
                         itemtype="http://schema.org/Person"><span class="name" itemprop="name"><a class="name-search"
                              href="/search?author1=Robert+Benamouzig&amp;sortspec=date&amp;submit=Submit">Robert Benamouzig</a></span>, 
                     </li>
                     <li class="contributor" id="contrib-5" itemprop="author" itemscope="itemscope"
                         itemtype="http://schema.org/Person"><span class="name" itemprop="name"><a class="name-search"
                              href="/search?author1=Robert+S.+Sandler&amp;sortspec=date&amp;submit=Submit">Robert S. Sandler</a></span>, 
                     </li>
                     <li class="contributor" id="contrib-6" itemprop="author" itemscope="itemscope"
                         itemtype="http://schema.org/Person"><span class="name" itemprop="name"><a class="name-search"
                              href="/search?author1=Matthew+J.+Grainge&amp;sortspec=date&amp;submit=Submit">Matthew J. Grainge</a></span>, 
                     </li>
                     <li class="contributor" id="contrib-7" itemprop="author" itemscope="itemscope"
                         itemtype="http://schema.org/Person"><span class="name" itemprop="name"><a class="name-search"
                              href="/search?author1=Stanislas+Chaussade&amp;sortspec=date&amp;submit=Submit">Stanislas Chaussade</a></span> and 
                     </li>
                     <li class="last" id="contrib-8"><span class="name"><a class="name-search"
                              href="/search?author1=John+A.+Baron&amp;sortspec=date&amp;submit=Submit">John A. Baron</a></span></li>
                  </ol>
                  <ol class="affiliation-list">
                     <li class="aff"><a id="aff-1" name="aff-1"></a><address><strong>Affiliations of authors:</strong> Department of Mathematics and Statistics, University of Vermont, Burlington, VT (BFC); Department of Epidemiology and Public
                           Health, Queens Medical Centre, University of Nottingham, Nottingham, UK (RFL, MJG); Department of Biostatistics and Bioinformatics
                           and the Cancer and Leukemia Group B Statistical Center, Duke University Medical Center, Durahm, NC (SH); Department of Gastroenterology,
                           Hopital Avicenne, Bobigny, France (RB); Department of Medicine, University of North Carolina School of Medicine, Chapel Hill,
                           NC (RSS); Department of Gastroenterology, Hopital Cochin–Université René Descartes, Paris, France (SC); Department of Community
                           and Family Medicine (BFC, JAB) and Department of Medicine (JAB), Dartmouth Medical School, Hanover, NH
                        </address>
                     </li>
                  </ol>
                  <ol class="corresp-list">
                     <li class="fn" id="corresp-1"><strong>Correspondence to:</strong><br /> Bernard F. Cole, PhD, Department of Mathematics and Statistics, University of Vermont, 16 Colchester Ave, Burlington, VT
                        05401 (e-mail: <span class="em-link"><span class="em-addr">ccole{at}cems.uvm.edu</span></span>).
                     </li>
                  </ol>
                  <ul class="history-list">
                     <li xmlns:hwp="http://schema.highwire.org/Journal" class="received"
                         hwp:start="2008-05-09"><span class="received-label">Received </span>May 9, 2008.
                     </li>
                     <li xmlns:hwp="http://schema.highwire.org/Journal" class="rev-recd"
                         hwp:start="2008-11-17"><span class="rev-recd-label">Revision received </span>November 17, 2008.
                     </li>
                     <li xmlns:hwp="http://schema.highwire.org/Journal" class="accepted"
                         hwp:start="2008-12-01"><span class="accepted-label">Accepted </span>December 1, 2008.
                     </li>
                  </ul>
               </div>
               <div class="section abstract" id="abstract-1" itemprop="description">
                  <div class="section-nav">
                     <div class="nav-placeholder"> </div><a href="#sec-11" title="Methods" class="next-section-link"><span>Next Section</span></a></div>
                  <h2>Abstract</h2>
                  <div id="sec-1" class="subsection">
                     <p id="p-1"><strong>Background</strong> Multiple lines of evidence indicate that aspirin has an antineoplastic effect in the large bowel. Randomized clinical trials
                        have been conducted to evaluate the effectiveness of aspirin for reducing the risk of colorectal adenomas. A meta-analysis
                        of these trials will provide more precise estimates of the aspirin effect, both overall and in subgroups.
                     </p>
                  </div>
                  <div id="sec-2" class="subsection">
                     <p id="p-2"><strong>Methods</strong> We combined data from all randomized double-blind placebo-controlled trials that evaluated aspirin for the prevention of
                        colorectal adenomas. We used random-effects meta-analysis to estimate risk ratios and 95% confidence intervals (CIs) for the
                        effect of aspirin on the occurrence of adenomas and of advanced lesions (ie, tubulovillous adenomas, villous adenomas, adenomas
                        ≥1 cm in diameter, adenomas with high-grade dysplasia, or invasive cancer). All statistical tests were two-sided.
                     </p>
                  </div>
                  <div id="sec-3" class="subsection">
                     <p id="p-3"><strong>Results</strong> We identified four clinical trials with 2967 randomly assigned participants. Each trial evaluated aspirin for the secondary
                        prevention of colorectal adenomas. Doses of aspirin tested ranged from 81 to 325 mg/d. The average age of participants at
                        baseline was 58 years, and 60% were male. Median follow-up was 33 months. A total of 2698 participants underwent colonoscopic
                        follow-up and were included in the analysis of adenoma occurrence and advanced-lesion occurrence after randomization. Among
                        these participants, adenomas were found in 424 (37%) of the 1156 participants allocated to placebo and in 507 (33%) of the
                        1542 participants allocated to any dose of aspirin. Advanced lesions were found in 12% of participants in the placebo group
                        and in 9% of participants allocated to any dose of aspirin. The pooled risk ratio of any adenoma for any dose of aspirin vs
                        placebo was 0.83 (95% CI = 0.72 to 0.96). This corresponded to an absolute risk reduction of 6.7% (95% CI = 3.2% to 10.2%).
                        For any advanced lesion, the pooled risk ratio was 0.72 (95% CI = 0.57 to 0.90). We found no statistically significant effect
                        modification for any of the baseline factors studied.
                     </p>
                  </div>
                  <div id="sec-4" class="subsection">
                     <p id="p-4"><strong>Conclusion</strong> Aspirin is effective for the prevention of colorectal adenomas in individuals with a history of these lesions.
                     </p>
                  </div>
               </div>
               <div class="boxed-text" id="boxed-text-1">
                  <div id="sec-5" class="subsection">
                     <h4>CONTEXT AND CAVEATS</h4>
                     <div id="sec-6" class="subsection">
                        <h5>Prior knowledge</h5>
                        <p id="p-5">Multiple lines of evidence including clinical trial data indicate that aspirin has an antineoplastic effect in the large bowel
                           and reduces the risk of colorectal adenomas. However, a quantitative summary of efficacy is missing.
                        </p>
                     </div>
                     <div id="sec-7" class="subsection">
                        <h5>Study design</h5>
                        <p id="p-6">A meta-analysis of the association between aspirin use and the occurrence of adenomas and of advanced lesions using participant
                           data from four randomized double-blind trials that evaluated higher-dose and/or lower-dose aspirin vs placebo for the secondary
                           prevention of colorectal adenomas.
                        </p>
                     </div>
                     <div id="sec-8" class="subsection">
                        <h5>Contribution</h5>
                        <p id="p-7">Among 2698 participants who underwent colonoscopic follow-up after randomization, adenomas were found in 37% of those allocated
                           to placebo and in 33% of those allocated to any dose of aspirin (advanced lesions were found in 12% and 9%, respectively).
                        </p>
                     </div>
                     <div id="sec-9" class="subsection">
                        <h5>Implications</h5>
                        <p id="p-8">This meta-analysis of clinical trial data indicates that aspirin reduces the risk of recurrence of colorectal adenomas.</p>
                     </div>
                     <div id="sec-10" class="subsection">
                        <h5>Limitations</h5>
                        <p id="p-9">Dose–response patterns were not interpretable because only two studies investigated lower-dose aspirin. An analysis of cardiovascular
                           and bleeding events was limited by the small numbers of events observed in any one trial. One trial was excluded from the
                           analysis of adverse events.
                        </p>
                        <p id="p-10"><em>From the Editors</em></p>
                     </div>
                  </div>
               </div>
               <p id="p-11">Over the past 30 years, compelling data have emerged suggesting that nonsteroidal anti-inflammatory drugs (NSAIDs), particularly
                  aspirin, can suppress carcinogenesis in the large bowel. For example, in numerous epidemiological studies, the use of aspirin
                  or other NSAIDs has been associated with a reduced risk of colorectal cancer (<a id="xref-ref-1-1" class="xref-bibr" href="#ref-1">1</a>), and pooled results from two clinical trials have shown a protective effect in the primary prevention of sporadic colorectal
                  cancer (<a id="xref-ref-2-1" class="xref-bibr" href="#ref-2">2</a>). In trials conducted among patients with familial adenomatous polyposis (<a id="xref-ref-3-1" class="xref-bibr" href="#ref-3">3</a>–<a id="xref-ref-7-1" class="xref-bibr" href="#ref-7">7</a>), treatment with other NSAIDS (sulindac or cyclooxygenase-2 inhibitors) caused existing adenomas to regress and suppressed
                  the emergence of new lesions.
               </p>
               <p id="p-12">In case–control and cohort studies (<a id="xref-ref-2-2" class="xref-bibr" href="#ref-2">2</a>,<a id="xref-ref-8-1" class="xref-bibr" href="#ref-8">8</a>,<a id="xref-ref-9-1" class="xref-bibr" href="#ref-9">9</a>), aspirin use was associated with a reduced risk of colorectal cancer, especially after 10 years of use. Clinical trial data
                  (<a id="xref-ref-2-3" class="xref-bibr" href="#ref-2">2</a>) also suggest that aspirin must be taken for many years before a protective effect on colorectal cancer emerges. The long
                  duration of use required to prevent invasive cancer may reflect the time required for cancer to develop from precursor lesions.
               </p>
               <p id="p-13">Colorectal adenomas—the precursors to most colorectal cancers—would be expected to reflect the chemopreventive effects of
                  aspirin sooner than invasive cancers because these lesions occur much earlier in the carcinogenic pathways. To date, results
                  of four randomized clinical trials that formally assessed the effect of aspirin on the risk of adenomas have been published
                  (<a id="xref-ref-10-1" class="xref-bibr" href="#ref-10">10</a>–<a id="xref-ref-13-1" class="xref-bibr" href="#ref-13">13</a>). Participants with a history of colorectal adenomas or cancer were recruited in each of the trials and were followed up
                  for subsequent new adenomas. Data from each of these trials suggest that aspirin reduces the risk of subsequent new adenomas,
                  but, to our knowledge, a quantitative summary of efficacy has not been reported. In addition, it is not clear what the dose–response
                  patterns are or if particular groups are resistant (or more sensitive) to the chemopreventive effect of aspirin.
               </p>
               <p id="p-14">To better characterize the apparent chemopreventive effect of aspirin in the large bowel, we performed a meta-analysis of
                  all available randomized clinical trials that investigated whether aspirin reduces the risk of colorectal adenomas.
               </p>
               <div class="section methods" id="sec-11">
                  <div class="section-nav"><a href="#abstract-1" title="Abstract" class="prev-section-link"><span>Previous Section</span></a><a href="#sec-15" title="Results" class="next-section-link"><span>Next Section</span></a></div>
                  <h2>Methods</h2>
                  <div id="sec-12" class="subsection">
                     <h3>Trial Inclusion Criteria</h3>
                     <p id="p-15">We identified candidate studies by conducting computerized searches of the Medline and Web of Science databases using the
                        terms “aspirin,” “acetylsalicylic acid,” “salicylates,” “adenoma,” and “randomized clinical trial.” We also consulted with
                        colleagues to identify unpublished studies that may exist. We included all placebo-controlled randomized trials of aspirin
                        (acetylsalicylic acid) in any dose as a chemopreventive agent for sporadic large-bowel adenomas. To be included in this meta-analysis,
                        a trial must have satisfied the following inclusion criteria: 1) the study was placebo controlled and double blinded; 2) individuals
                        with familial adenomatous polyposis were excluded; 3) participants were treated for at least 1 year; 4) for each participant,
                        colorectal polyp status at baseline was assessed with complete colonoscopy and no polyps were knowingly left in the bowel
                        at that time; and 5) colorectal polyp occurrence after randomization was assessed by colonoscopic follow-up. In addition,
                        each trial had to have obtained written informed consent from each participant and must have had appropriate institutional
                        review board (IRB) approval.
                     </p>
                  </div>
                  <div id="sec-13" class="subsection">
                     <h3>Data Collection</h3>
                     <p id="p-16">Rather than combine published (or provided) summary statistics from each study, we obtained participant-level data from each
                        identified trial, a preferred approach to meta-analysis (<a id="xref-ref-14-1" class="xref-bibr" href="#ref-14">14</a>). We sought the following data elements: randomized aspirin or placebo treatment group; age at study entry (in years at last
                        birthday); sex; race; baseline body mass index (BMI); number of lifetime adenomas before randomization; family history of
                        colorectal cancer; baseline smoking status; duration of randomized treatment; pill-taking compliance; occurrence and timing
                        of death during the treatment period; occurrence and timing of myocardial infarctions, strokes, major bleeding, or new cancer
                        diagnoses during the treatment period; and timing and outcome of each colonoscopic follow-up examination during the treatment
                        period, including the type, size, and location of each adenoma found and whether high-grade dysplasia was present. These data,
                        if available, were sent in a de-identified data file to Dartmouth Medical School for analysis as a combined dataset. This
                        study was determined to be exempt from IRB review by the Dartmouth College Human Subjects Review Committee.
                     </p>
                  </div>
                  <div id="sec-14" class="subsection">
                     <h3>Statistical Analysis</h3>
                     <p id="p-17">The primary endpoint was the occurrence of any colorectal adenoma after randomization. Secondary endpoints were the occurrence
                        of advanced lesions, defined as tubulovillous adenomas (25%–75% villous features), villous adenomas (≥75% villous features),
                        large adenomas (≥1 cm in diameter), adenomas with high-grade dysplasia, or invasive cancer, and the occurrence of adverse
                        events. The statistical analysis of the combined datasets followed standard random-effects meta-analysis methods (<a id="xref-ref-15-1" class="xref-bibr" href="#ref-15">15</a>–<a id="xref-ref-17-1" class="xref-bibr" href="#ref-17">17</a>) in a two-stage approach. In the first stage, each clinical trial was analyzed separately to obtain trial-specific estimates
                        of the relative risk of adenoma and advanced lesions for the aspirin group vs the placebo group. The trial-specific risk ratios
                        were then combined using standard methods for random-effects meta-analysis (<a id="xref-ref-15-2" class="xref-bibr" href="#ref-15">15</a>). A similar method was used to combine trial-specific absolute risk reductions. All <em>P</em> values were derived from two-sided tests, and we considered a <em>P</em> value less than .05 to be statistically significant. Between-study heterogeneity was assessed using the <em>Q</em> statistic and the <em>I</em><sup> 2</sup> statistic. An <em>I </em><sup>2</sup> value of greater than 50%, or a <em>P</em> value less than .05 for the <em>Q</em> statistic, was taken to indicate heterogeneity (<a id="xref-ref-18-1" class="xref-bibr" href="#ref-18">18</a>,<a id="xref-ref-19-1" class="xref-bibr" href="#ref-19">19</a>). Within each clinical trial, the analysis population was defined as all randomly assigned participants who had undergone
                        at least one follow-up colonoscopy. This approach represents a modified intention-to-treat analysis.
                     </p>
                     <p id="p-18">We used forest plots to summarize overall results for the effect of aspirin on the risks of any adenoma and any advanced lesion.
                        Subgroup analyses were performed to evaluate the consistency of the aspirin treatment effect within specific subgroups of
                        patients defined according to their baseline characteristics. These analyses were performed using the same methods as described
                        above, but they focused on data for the subgroup of interest. Wald tests were used to assess the interaction between aspirin
                        and subgroup. Six subgroup factors were defined in the analysis protocol: sex; age (≤54, 55–63, or ≥64 years, based on tertiles
                        of the data); BMI [&lt;25, 25–29.9, or ≥30.0 kg/m<sup>2</sup>, based on cut points established by the National Heart, Lung and Blood Institute (<a id="xref-ref-20-1" class="xref-bibr" href="#ref-20">20</a>)]; family history of colorectal cancer, defined as a first-degree relative diagnosed with the disease (present or absent);
                        number of lifetime adenomas (1 or ≥2, to divide the sample into two groups of similar size); and the presence of advanced
                        lesions at the examination that was required to determine study eligibility (present or absent). We also performed analyses
                        that considered colonoscopic examinations that occurred within four follow-up intervals following randomization: 0 to &lt;12,
                        12 to &lt;24, 24 to &lt;38, and ≥38 months. These intervals were chosen to compare effects from year to year after randomization.
                        However, because most of the clinical trials specified a 3-year follow-up interval, we set the final cut point at 38 months
                        rather than 36 months. This cut point ensured that follow-up examinations that occurred near the planned examination time
                        fell within only one of the analysis time intervals (ie, the interval from 24 to &lt;38 months).
                     </p>
                  </div>
               </div>
               <div class="section results" id="sec-15">
                  <div class="section-nav"><a href="#sec-11" title="Methods" class="prev-section-link"><span>Previous Section</span></a><a href="#sec-24" title="Discussion" class="next-section-link"><span>Next Section</span></a></div>
                  <h2>Results</h2>
                  <div id="sec-16" class="subsection">
                     <h3>Trials Identified</h3>
                     <p id="p-19">We identified four clinical trials that satisfied the inclusion criteria: the Aspirin/Folate Polyp Prevention Study (AFPPS)
                        (<a id="xref-ref-10-2" class="xref-bibr" href="#ref-10">10</a>), the Colorectal Adenoma Prevention Study [Cancer and Leukemia Group B (CALGB) 9270] (<a id="xref-ref-11-1" class="xref-bibr" href="#ref-11">11</a>), the United Kingdom Colorectal Adenoma Prevention (ukCAP) Study (<a id="xref-ref-12-1" class="xref-bibr" href="#ref-12">12</a>), and the Association pour la Prevention par l’Aspirine du Cancer Colorectal (APACC) Study (<a id="xref-ref-13-2" class="xref-bibr" href="#ref-13">13</a>). <a id="xref-table-wrap-1-1" class="xref-table" href="#T1">Table 1</a> summarizes the trial designs. Three of the four trials (AFPPS, ukCAP, and APACC) recruited participants with a recent history
                        of sporadic colorectal adenoma and excluded individuals with a history of invasive large-bowel cancer, and one trial (CALGB
                        9270) specifically recruited patients who had been treated for colorectal cancer. Other eligibility criteria for the trials
                        were similar—each trial excluded individuals with inflammatory bowel disease, those with a clinical need for aspirin treatment,
                        and those who could not take aspirin.
                     </p>
                     <div class="table pos-float" id="T1">
                        <div class="table-inline">
                           <div class="callout"><span>View this table:</span><ul class="callout-links">
                                 <li><a href="256/T1.expansion.html">In this window</a></li>
                                 <li><a class="in-nw" href="256/T1.expansion.html">In a new window</a></li>
                              </ul>
                           </div>
                        </div>
                        <div class="table-caption"><span class="table-label">Table 1</span> 
                           <p id="p-20" class="first-child">Summary of trial designs*</p>
                           <div class="sb-div caption-clear"></div>
                        </div>
                     </div>
                     <p id="p-22">All four studies used an adenoma endpoint. Two trials (AFPPS and APACC) compared lower-dose aspirin (defined as 81 or 160
                        mg/d) and higher-dose aspirin (defined as 300 or 325 mg/d) with placebo. The remaining trials (CALGB 9270 and ukCAP) compared
                        higher-dose aspirin with placebo.
                     </p>
                     <p id="p-23">Each of the trials had a defined endoscopy follow-up schedule. AFPPS and ukCAP intended to examine participants 3 years after
                        the baseline examination, and APACC examined participants at 1 and 4 years after the baseline examination. CALGB 9270 examined
                        participants with early-stage disease at 4 years after the baseline examination and all other patients at 3 years after the
                        baseline examination. This trial was stopped early because of the efficacy of the intervention. AFPPS and APACC each had central
                        pathology review of lesions removed from the large bowel during follow-up examinations. CALGB 9270 and ukCAP relied solely
                        on local pathologists to determine lesion characteristics.
                     </p>
                     <p id="p-24">Follow-up for adverse events varied considerably across trials. AFPPS attempted to follow up all participants through the
                        dates of the expected year 3 examinations, whereas in APACC and ukCAP, adverse event data were ascertained only for participants
                        who were on treatment or who had study examinations. Adverse event data for CALGB 9270 were considered unreliable by the study
                        investigators because of inconsistencies in the computerized database, and thus the data regarding bleeding, cardiovascular
                        events, and cancer diagnoses from this trial were not included in this analysis. We included only the deaths that occurred
                        during the treatment period of all studies, including CALGB 9270, which was terminated early due to efficacy.
                     </p>
                     <p id="p-25">Primary analyses reports have been published for AFPPS (<a id="xref-ref-10-3" class="xref-bibr" href="#ref-10">10</a>), CALGB 9270 (<a id="xref-ref-11-2" class="xref-bibr" href="#ref-11">11</a>), and ukCAP (<a id="xref-ref-12-2" class="xref-bibr" href="#ref-12">12</a>). APACC has reported year 1 results only (<a id="xref-ref-13-3" class="xref-bibr" href="#ref-13">13</a>).
                     </p>
                  </div>
                  <div id="sec-17" class="subsection">
                     <h3>Characteristics of the Study Participants</h3>
                     <p id="p-26"><a id="xref-table-wrap-2-1" class="xref-table" href="#T2">Table 2</a> describes the baseline characteristics of all 2967 randomly assigned participants by treatment group. Of these, 1289 participants
                        were allocated to placebo and 1678 to aspirin. A total of 450 participants were randomly assigned to lower-dose aspirin and
                        1228 to higher-dose aspirin. The mean age of all participants was approximately 58 years, and approximately 60% were male.
                        Smoking status was not available from CALGB 9270, nor was information regarding family history of colorectal cancer. Data
                        on race were not available from APACC. Consequently, data regarding some characteristics were missing for substantial proportions
                        of the participants. Most participants (71%) were non-Hispanic white or had a BMI of 25 kg/m<sup>2</sup> or higher. Most (54%) of the participants whose adenoma history was known had only one lifetime adenoma. Among those with
                        information available regarding family history of colorectal cancer, 31% had a first-degree relative who had been diagnosed
                        with colorectal cancer. The high proportions of males, those with unknown number of lifetime adenomas, and those with a family
                        history of colorectal cancer in the lower-dose aspirin group reflect the characteristics of participants in the two studies
                        that offered two aspirin doses, not imbalances in randomization.
                     </p>
                     <div class="table pos-float" id="T2">
                        <div class="table-inline">
                           <div class="callout"><span>View this table:</span><ul class="callout-links">
                                 <li><a href="256/T2.expansion.html">In this window</a></li>
                                 <li><a class="in-nw" href="256/T2.expansion.html">In a new window</a></li>
                              </ul>
                           </div>
                        </div>
                        <div class="table-caption"><span class="table-label">Table 2</span> 
                           <p id="p-27" class="first-child">Baseline characteristics of participants in all trials</p>
                           <div class="sb-div caption-clear"></div>
                        </div>
                     </div>
                     <p id="p-28">All of the trials required participants to avoid taking aspirin and NSAIDs during the treatment period of the trial. Therefore,
                        very few participants were regular users of these drugs before randomization. Rates of regular use (defined as use at least
                        3 d/wk) before randomization did not exceed 5% in any of the studies, and treatment groups were not statistically significantly
                        unbalanced in this regard.
                     </p>
                  </div>
                  <div id="sec-18" class="subsection">
                     <h3>Compliance and Follow-up</h3>
                     <p id="p-29">Compliance with the study treatments and procedures was generally good. Overall pill-taking compliance (expressed as the percentage
                        of expected number of study pills taken) tended to be slightly higher in the any-dose aspirin group than in the placebo group
                        (<a id="xref-table-wrap-3-1" class="xref-table" href="#T3">Table 3</a>). Among the four studies, mean pill-taking compliance ranged from approximately 69% to approximately 92%. At least 81% of
                        participants in each of the studies and at least 90% of the participants in three studies (AFPPS, ukCAP, and APACC) had at
                        least one follow-up examination (<a href="http://jnci.oxfordjournals.org/cgi/content/full/djn485/DC1">Supplementary Table 1</a>, available online). (The early termination of CALGB 9270 contributed to the lower percentage of participants with colonoscopic
                        follow-up in that study.) In total, 2698 participants underwent colonoscopic follow-up. The remaining 269 participants were
                        either lost to follow-up or died and were excluded from the analysis of adenoma and advanced-lesion occurrence. The median
                        follow-up of all participants was approximately 33 months. APACC included a 4-year examination and thus had the longest median
                        follow-up (47.2 months vs 32.2, 31.3, and 37.5 months for AFPPS, CALGB 9270, and ukCAP, respectively). Follow-up duration
                        and rate of colonoscopic follow-up were well balanced across the treatment groups (<a href="http://jnci.oxfordjournals.org/cgi/content/full/djn485/DC1">Supplementary Table 1</a>, available online).
                     </p>
                     <div class="table pos-float" id="T3">
                        <div class="table-inline">
                           <div class="callout"><span>View this table:</span><ul class="callout-links">
                                 <li><a href="256/T3.expansion.html">In this window</a></li>
                                 <li><a class="in-nw" href="256/T3.expansion.html">In a new window</a></li>
                              </ul>
                           </div>
                        </div>
                        <div class="table-caption"><span class="table-label">Table 3</span> 
                           <p id="p-30" class="first-child">Overall pill-taking compliance*</p>
                           <div class="sb-div caption-clear"></div>
                        </div>
                     </div>
                  </div>
                  <div id="sec-19" class="subsection">
                     <h3>Adenoma and Advanced-Lesion Occurrence</h3>
                     <p id="p-32">The analyses of adenoma occurrence and advanced-lesion occurrence after randomization were restricted to the 2698 participants
                        for whom colonoscopic follow-up information was available. Overall, approximately 35% of participants with colonoscopic follow-up
                        were diagnosed with one or more recurrent adenomas, and the proportions varied considerably across studies, ranging from approximately
                        22% to 52% of participants. The lowest proportion was seen in CALGB 9270 (22%), which possibly reflects the fact that these
                        participants did not have an entire colorectal mucosa left at risk after undergoing a colon or rectum resection for their
                        cancer.
                     </p>
                     <p id="p-33"><a id="xref-fig-1-1" class="xref-fig" href="#F1">Figure 1</a> summarizes the random-effects meta-analysis comparing aspirin in any dose to placebo. Among participants with colonoscopic
                        follow-up, adenomas were found in 424 (37%) of the 1156 participants allocated to placebo and in 507 (33%) of the 1542 participants
                        allocated to any dose of aspirin (<a id="xref-fig-1-2" class="xref-fig" href="#F1">Figure 1</a>). We observed a statistically significant 17% relative reduction in the risk of any adenoma for aspirin in any dose vs placebo
                        (pooled risk ratio [RR] = 0.83; 95% confidence interval [CI] = 0.72 to 0.96). This corresponded to a statistically significant
                        6.7% (95% CI = 3.2% to 10.2%) absolute risk reduction. Among participants with colonoscopic follow-up, advanced lesions were
                        found in 137 (12%) participants in the placebo group and in 134 (9%) participants allocated to any dose of aspirin (<a id="xref-fig-1-3" class="xref-fig" href="#F1">Figure 1</a>), which corresponded to a statistically significant relative risk reduction of 28% for aspirin in any dose (RR = 0.72; 95%
                        CI = 0.57 to 0.90).
                     </p>
                     <div id="F1" class="fig pos-float odd">
                        <div class="fig-inline"><a href="256/F1.expansion.html"><img alt="Figure 1" src="256/F1.small.gif" /></a><div class="callout"><span>View larger version:</span><ul class="callout-links">
                                 <li><a href="256/F1.expansion.html">In this window</a></li>
                                 <li><a class="in-nw" href="256/F1.expansion.html">In a new window</a></li>
                              </ul>
                              <ul class="fig-services">
                                 <li class="ppt-link"><a href="/powerpoint/101/4/256/F1">Download as PowerPoint Slide</a></li>
                              </ul>
                           </div>
                        </div>
                        <div class="fig-caption"><span class="fig-label">Figure 1</span> 
                           <p id="p-34" class="first-child">Random-effects risk ratio forest plot comparing any aspirin vs placebo. Trial-specific risk ratios are shown as <strong>black squares</strong>, with the size of the square being inversely proportional to the trial-specific risk ratio variance. <strong>Horizontal lines</strong> represent 95% confidence intervals for the trial-specific risk ratios. Pooled risk ratios are shown as <strong>diamonds</strong>. The middle of each diamond corresponds to the risk ratio, and the width of each diamond represents the 95% confidence interval.
                              The <strong>vertical dashed lines</strong> provide a visual comparison of the pooled risk ratio with the corresponding trial-specific risk ratios. Tests for heterogeneity
                              are as follows. For any adenoma, <em>Q</em> = 5.13 (<em>P</em> = 0.16) and <em>I </em><sup>2</sup> = 41.5. For advanced lesion, <em>Q</em> = 1.27 (<em>P</em> = .74) and <em>I</em><sup> 2</sup> = 0.0. AFPPS = Aspirin/Folate Polyp Prevention Study; APACC = Association pour la Prevention par l’Aspirine du Cancer Colorectal;
                              CALGB = Cancer and Leukemia Group B; CI = confidence interval; ukCAP = United Kingdom Colorectal Adenoma Prevention.
                           </p>
                           <div class="sb-div caption-clear"></div>
                        </div>
                     </div>
                     <p id="p-35"><a id="xref-fig-2-1" class="xref-fig" href="#F2">Figures 2</a> and <a id="xref-fig-3-1" class="xref-fig" href="#F3">3</a> summarize the pooled comparisons of higher-dose aspirin vs placebo and lower-dose aspirin vs placebo, respectively. Among
                        the 1108 participants who were randomly assigned to higher-dose aspirin and who underwent colonoscopic follow-up, adenomas
                        were found in 335 (30%) and advanced lesions were found in 92 (8%). Among the 434 participants who were randomly assigned
                        to lower-dose aspirin and who underwent colonoscopic follow-up, adenomas were found in 172 (40%) and advanced lesions were
                        found in 42 (10%). For high-dose aspirin vs placebo, we observed a non–statistically significant relative risk reduction of
                        15% for any adenoma (RR = 0.85; 95% CI = 0.70 to 1.03); however, the absolute risk reduction of 5.7% was statistically significant
                        (95% CI = 1.5% to 9.9%). We observed a statistically significant relative risk reduction of 29% for advanced lesions (RR =
                        0.71; 95% CI = 0.56 to 0.92) (<a id="xref-fig-2-2" class="xref-fig" href="#F2">Figure 2</a>). For low-dose aspirin vs placebo, we observed a statistically significant relative risk reduction of 17% for any adenoma
                        (RR = 0.83; 95% CI = 0.71 to 0.96), which corresponded to a statistically significant absolute risk reduction of 8.4% (95%
                        CI = 1.9% to 14.8%). We also observed a non–statistically significant relative risk reduction of 17% for advanced lesions
                        (RR = 0.83; 95% CI = 0.44 to 1.58) (<a id="xref-fig-3-2" class="xref-fig" href="#F3">Figure 3</a>).
                     </p>
                     <div id="F2" class="fig pos-float odd">
                        <div class="fig-inline"><a href="256/F2.expansion.html"><img alt="Figure 2" src="256/F2.small.gif" /></a><div class="callout"><span>View larger version:</span><ul class="callout-links">
                                 <li><a href="256/F2.expansion.html">In this window</a></li>
                                 <li><a class="in-nw" href="256/F2.expansion.html">In a new window</a></li>
                              </ul>
                              <ul class="fig-services">
                                 <li class="ppt-link"><a href="/powerpoint/101/4/256/F2">Download as PowerPoint Slide</a></li>
                              </ul>
                           </div>
                        </div>
                        <div class="fig-caption"><span class="fig-label">Figure 2</span> 
                           <p id="p-36" class="first-child">Random-effects risk ratio forest plot comparing higher-dose aspirin (300 or 325 mg/d) vs placebo. Trial-specific risk ratios
                              are shown as <strong>black squares</strong>, with the size of the square being inversely proportional to the trial-specific risk ratio variance. <strong>Horizontal lines</strong> represent 95% confidence intervals for the trial-specific risk ratios. Pooled risk ratios are shown as <strong>diamonds</strong>. The middle of each diamond corresponds to the risk ratio, and the width of each diamond represents the 95% confidence interval.
                              The <strong>vertical dashed lines</strong> provide a visual comparison of the pooled risk ratio with the corresponding trial-specific risk ratios. Tests for heterogeneity
                              are as follows. For any adenoma, <em>Q</em> = 7.51 (<em>P</em> = .057) and <em>I</em><sup> 2</sup> = 60.1. For advanced lesion, <em>Q</em> = 1.87 (<em>P</em> = .60) and <em>I</em><sup> 2</sup>=0.0. AFPPS = Aspirin/Folate Polyp Prevention Study; APACC = Association pour la Prevention par l’Aspirine du Cancer Colorectal;
                              CALGB = Cancer and Leukemia Group B; CI = confidence interval; ukCAP = United Kingdom Colorectal Adenoma Prevention.
                           </p>
                           <div class="sb-div caption-clear"></div>
                        </div>
                     </div>
                     <div id="F3" class="fig pos-float odd">
                        <div class="fig-inline"><a href="256/F3.expansion.html"><img alt="Figure 3" src="256/F3.small.gif" /></a><div class="callout"><span>View larger version:</span><ul class="callout-links">
                                 <li><a href="256/F3.expansion.html">In this window</a></li>
                                 <li><a class="in-nw" href="256/F3.expansion.html">In a new window</a></li>
                              </ul>
                              <ul class="fig-services">
                                 <li class="ppt-link"><a href="/powerpoint/101/4/256/F3">Download as PowerPoint Slide</a></li>
                              </ul>
                           </div>
                        </div>
                        <div class="fig-caption"><span class="fig-label">Figure 3</span> 
                           <p id="p-37" class="first-child">Random-effects risk ratio forest plot comparing lower-dose aspirin (81 or 160 mg/d) vs placebo. Trial-specific risk ratios
                              are shown as <strong>black squares</strong>, with the size of the square being inversely proportional to the trial-specific risk ratio variance. <strong>Horizontal lines</strong> represent 95% confidence intervals for the trial-specific risk ratios. Pooled risk ratios are shown as <strong>diamonds</strong>. The middle of each diamond corresponds to the risk ratio, and the width of each diamond represents the 95% confidence interval.
                              The <strong>vertical dashed lines</strong> provide a visual comparison of the pooled risk ratio with the corresponding trial-specific risk ratios. Tests for heterogeneity
                              are as follows. For any adenoma, <em>Q</em> = 0.21 (<em>P</em> = .65) and <em>I</em><sup>2</sup> = 0.0. For advanced lesion, <em>Q</em> = 2.89 (<em>P</em> = .089) and <em>I</em><sup>2</sup> = 65.4. AFPPS = Aspirin/Folate Polyp Prevention Study; APACC = Association pour la Prevention par l’Aspirine du Cancer Colorectal;
                              CI = confidence interval.
                           </p>
                           <div class="sb-div caption-clear"></div>
                        </div>
                     </div>
                     <p id="p-38">We compared higher-dose aspirin vs lower-dose aspirin using the two trials that provided relevant data (AFPPS and APACC).
                        This analysis involved 849 participants (415 allocated to higher-dose aspirin and 434 allocated to lower-dose aspirin). The
                        pooled risk ratio comparing higher-dose aspirin vs lower-dose aspirin was 1.18 (95% CI = 1.01 to 1.37), with an absolute risk
                        reduction of 7.0% (95% CI = 0.4% to 13.6%) in favor of lower-dose aspirin. For any advanced lesion, the pooled risk ratio
                        was 0.89 (95% CI = 0.32 to 2.47).
                     </p>
                     <p id="p-39">There was evidence of between-study heterogeneity for the following comparisons based on relative risk: higher-dose aspirin
                        vs placebo for any adenoma (<em>Q</em> = 7.51, <em>P</em> = .057; <em>I</em><sup>2</sup> = 60.1%), lower-dose aspirin vs placebo for advanced lesions (<em>Q</em> = 2.89, <em>P</em> = .089; <em>I</em><sup>2</sup> = 65.4%), and higher-dose aspirin vs lower-dose aspirin for advanced lesions (<em>Q</em> = 4.25, <em>P</em> = .04; <em>I</em><sup>2</sup> = 76.5). For the first two of these three comparisons, heterogeneity was established solely based on an <em>I</em><sup>2</sup> statistic greater than 50%. No statistically significant heterogeneity was observed for comparisons based on absolute risk
                        reductions.
                     </p>
                  </div>
                  <div id="sec-20" class="subsection">
                     <h3>Subgroup Analyses</h3>
                     <p id="p-40">Results of the random-effects meta-analysis for all adenomas according to subgroups of participants revealed no statistically
                        significant effect modification for any of the baseline factors studied (<a id="xref-fig-4-1" class="xref-fig" href="#F4">Figure 4</a>). However, the estimated effect of aspirin in any dose on advanced lesions was substantially greater among those with a family
                        history of colorectal cancer (RR = 0.53; 95% CI = 0.33 to 0.83) than among those without (RR = 0.92; 95% CI = 0.67 to 1.28;
                        <em>P</em><sub>interaction</sub> = .05).
                     </p>
                     <div id="F4" class="fig pos-float odd">
                        <div class="fig-inline"><a href="256/F4.expansion.html"><img alt="Figure 4" src="256/F4.small.gif" /></a><div class="callout"><span>View larger version:</span><ul class="callout-links">
                                 <li><a href="256/F4.expansion.html">In this window</a></li>
                                 <li><a class="in-nw" href="256/F4.expansion.html">In a new window</a></li>
                              </ul>
                              <ul class="fig-services">
                                 <li class="ppt-link"><a href="/powerpoint/101/4/256/F4">Download as PowerPoint Slide</a></li>
                              </ul>
                           </div>
                        </div>
                        <div class="fig-caption"><span class="fig-label">Figure 4</span> 
                           <p id="p-41" class="first-child">Random-effects risk ratio forest plot comparing any aspirin vs placebo by subgroups. <strong>A)</strong> Any adenoma. <strong>B)</strong> Advanced lesion. Subgroup-specific risk ratios are shown as <strong>black squares</strong>, with the size of the square being inversely proportional to the subgroup-specific risk ratio variance. <strong>Horizontal lines</strong> represent 95% confidence intervals for the subgroup-specific risk ratios. Overall pooled risk ratios are shown as <strong>diamonds</strong>. The middle of each diamond corresponds to the risk ratio, and the width of each diamond represents the 95% confidence interval.
                              The <strong>vertical dashed line</strong> provides a visual comparison of the pooled risk ratio with the subgroup-specific risk ratios. <em>P</em> values (two-sided) are based on Wald tests for interaction. Among those with follow-up data, body mass index was missing
                              for 173 participants in the aspirin groups and 142 participants in the placebo group; family history of colorectal cancer
                              was missing for 532 participants in the aspirin groups and 451 participants in the placebo group, including all participants
                              in Cancer and Leukemia Group B (CALGB 9270); number of lifetime adenomas at baseline was missing for 261 participants in the
                              aspirin groups and 260 participants in the placebo group, including all participants in CALGB 9270; advanced-lesion status
                              at baseline was missing for 96 participants in the aspirin groups and 71 participants in the placebo group, with participants
                              in CALGB 9270 being excluded from this subgroup analysis. CI = confidence interval.
                           </p>
                           <div class="sb-div caption-clear"></div>
                        </div>
                     </div>
                  </div>
                  <div id="sec-21" class="subsection">
                     <h3>Analyses by Time of Examination</h3>
                     <p id="p-42">Random-effects meta-analysis for any-dose aspirin vs placebo by time since randomization revealed that greatest reduction
                        in risk for all adenomas occurred during the first year of follow-up (RR = 0.62; 95% CI = 0.48 to 0.81) and that aspirin had
                        no effect on risk beyond 38 months (RR = 0.99; 95% CI = 0.78 to 1.26) (<a id="xref-fig-5-1" class="xref-fig" href="#F5">Figure 5</a>). Most of the follow-up examinations occurred 24–38 months after randomization; for this time period, the pooled risk ratio
                        was 0.84 (95% CI = 0.74 to 0.96). For advanced lesions, the most pronounced effects were also in the first year of follow-up,
                        when the pooled risk ratio comparing aspirin in any dose vs placebo was 0.47 (95% CI = 0.24 to 0.90); the corresponding pooled
                        risk ratios for the subsequent time intervals were 0.91 (95% CI = 0.42 to 2.00) for 12–24 months, 0.72 (95% CI = 0.52 to 1.00)
                        for 23–38 months, and 0.71 (95% CI = 0.37 to 1.35) for 38 months or longer.
                     </p>
                     <div id="F5" class="fig pos-float odd">
                        <div class="fig-inline"><a href="256/F5.expansion.html"><img alt="Figure 5" src="256/F5.small.gif" /></a><div class="callout"><span>View larger version:</span><ul class="callout-links">
                                 <li><a href="256/F5.expansion.html">In this window</a></li>
                                 <li><a class="in-nw" href="256/F5.expansion.html">In a new window</a></li>
                              </ul>
                              <ul class="fig-services">
                                 <li class="ppt-link"><a href="/powerpoint/101/4/256/F5">Download as PowerPoint Slide</a></li>
                              </ul>
                           </div>
                        </div>
                        <div class="fig-caption"><span class="fig-label">Figure 5</span> 
                           <p id="p-43" class="first-child">Random-effects risk ratio forest plot comparing any aspirin vs placebo in terms of adenoma risk by time interval after randomization.
                              Trial-specific risk ratios are shown as <strong>black squares</strong>, with the size of the square being inversely proportional to the trial-specific risk ratio variance. <strong>Horizontal lines</strong> represent 95% confidence intervals for the trial-specific risk ratios. Pooled risk ratios are shown as <strong>diamonds</strong>. The middle of each diamond corresponds to the risk ratio, and the width of each diamond represents the 95% confidence interval.
                              The <strong>vertical dashed lines</strong> provide a visual comparison of the pooled risk ratios with the corresponding trial-specific risk ratios. *The AFPPS trial
                              had no examinations during the 0- to 12-month interval. †The APACC trial had only two examinations during the 24- to 38-month
                              interval. AFPPS = Aspirin/Folate Polyp Prevention Study; CALGB = Cancer and Leukemia Group B; APACC = Association pour la
                              Prevention par l’Aspirine du Cancer Colorectal; CI = confidence interval; ukCAP = United Kingdom Colorectal Adenoma Prevention.
                           </p>
                           <div class="sb-div caption-clear"></div>
                        </div>
                     </div>
                  </div>
                  <div id="sec-22" class="subsection">
                     <h3>Colorectal Cancer Occurrence</h3>
                     <p id="p-44">The AFPPS, ukCAP, and APACC trials reported incident colorectal cancer. CALGB 9270 was not included in this analysis because
                        it studied a population with a history of colorectal cancer, whereas the remaining trials involved participants with no history
                        of colorectal cancer. As would be expected in any population that was under endoscopic surveillance, the numbers of colorectal
                        cancers observed were small. Across the combined AFPPS, ukCAP, and APACC study populations, the percentage of participants
                        diagnosed with incident colorectal cancer was similar in the any-dose aspirin and placebo groups (0.54% vs 0.62%, respectively;
                        <em>P</em> = .81).
                     </p>
                  </div>
                  <div id="sec-23" class="subsection">
                     <h3>Adverse Events</h3>
                     <p id="p-45">Serious adverse events after randomization were uncommon (<a id="xref-table-wrap-4-1" class="xref-table" href="#T4">Table 4</a>). Rates of death (ie, the percentages of participants who died) were similar in the any-dose aspirin and placebo groups (0.95%
                        vs 0.85%, respectively; <em>P</em> = .85), as were the rates of myocardial infarction (0.48% vs 0.31%; <em>P</em> = .57). Of the 12 participants who had a stroke, all were randomly assigned to an aspirin group (<em>P</em> = .002). Most of the stroke cases were apparently thrombotic events; only one—in a participant with a subarachnoid hemorrhage—was
                        thought to be hemorrhagic. Rates of major bleeding were similar among participants allocated to any-dose aspirin and those
                        allocated to placebo (2.50% and 2.79%, respectively; <em>P</em> = .64). Rates of new cancer diagnoses (ie, the percentages of participants who received a new diagnosis of any invasive cancer)
                        were not statistically significantly different in the any-dose aspirin and placebo groups (2.62% vs 1.86%, respectively; <em>P</em> = .18), although the invasive cancer rate in the any-dose aspirin group was somewhat higher than that in the placebo group.
                     </p>
                     <div class="table pos-float" id="T4">
                        <div class="table-inline">
                           <div class="callout"><span>View this table:</span><ul class="callout-links">
                                 <li><a href="256/T4.expansion.html">In this window</a></li>
                                 <li><a class="in-nw" href="256/T4.expansion.html">In a new window</a></li>
                              </ul>
                           </div>
                        </div>
                        <div class="table-caption"><span class="table-label">Table 4</span> 
                           <p id="p-46" class="first-child">Adverse events in all trials combined</p>
                           <div class="sb-div caption-clear"></div>
                        </div>
                     </div>
                  </div>
               </div>
               <div class="section discussion" id="sec-24">
                  <div class="section-nav"><a href="#sec-15" title="Results" class="prev-section-link"><span>Previous Section</span></a><a href="#sec-25" title="Funding" class="next-section-link"><span>Next Section</span></a></div>
                  <h2>Discussion</h2>
                  <p id="p-48">We obtained data from all randomized trials that studied aspirin for the chemoprevention of colorectal adenomas and used patient-level
                     data to conduct a meta-analysis. In aggregate, nearly 3000 participants were included in four trials that were conducted in
                     the late 1990s. Two trials studied 300 or 325 mg aspirin vs placebo; the other two trials included a lower dose of aspirin.
                     Three trials recruited patients with recent adenomas, and one trial enrolled patients with colorectal cancer who had received
                     curative treatment. Each of the trials had a 3- or 4-year intervention period. Compliance and follow-up in the trials were
                     generally quite good.
                  </p>
                  <p id="p-49">Overall, we found a statistically significant 17% decrease in the relative risk of adenoma for aspirin in any dose vs placebo,
                     which corresponded to a 6.7% absolute risk reduction. We also observed a 28% decrease in the relative risk of advanced lesions.
                     All of the trials included in this meta-analysis involved a higher-dose aspirin arm (≥300 mg/d). In comparisons of higher-dose
                     aspirin vs placebo, there was a 15% non–statistically significant decrease in the relative risk of any adenoma; however, the
                     corresponding absolute risk reduction of 5.7% was statistically significant. We observed a statistically significant 29% reduction
                     in the relative risk of advanced lesions for higher-dose aspirin vs placebo. In the two trials that evaluated lower doses
                     of aspirin (doses of ≤160 mg/d) vs placebo, there was a statistically significant 17% decrease in the relative risk of any
                     adenoma (absolute risk reduction = 8.4%) and a non–statistically significant 17% reduction in the relative risk of advanced
                     lesions. These comparisons of the two dose levels with placebo suggest that there is no difference between higher- and lower-dose
                     aspirin in the effect on all adenomas and that higher-dose aspirin provides a greater risk reduction than lower-dose aspirin
                     for advanced lesions. However, a direct comparison of higher-dose vs lower-dose aspirin showed statistically significantly
                     greater risk reduction for all adenomas with lower-dose aspirin. A similar comparison for advanced lesions yielded inconsistent
                     and highly variable results. The difference between these findings and the comparisons with placebo is likely due to the limited
                     or lack of efficacy of higher-dose aspirin in the two studies that also investigated the lower doses.
                  </p>
                  <p id="p-50">In general, the most reliable dose–response findings are those derived from studies that investigate multiple doses in a single
                     population. The surprising lack of efficacy of the higher aspirin doses in the two multiple-dose trials, together with the
                     unusual dose–response patterns (ie, greater efficacy with lower dose) that were observed in those trials, prevents secure
                     conclusions regarding the relative efficacy of lower-dose vs higher-dose aspirin.
                  </p>
                  <p id="p-51">For any aspirin dose and for higher-dose aspirin, the effects observed were stronger for advanced lesions than for any adenomas.
                     The same pattern has been observed in randomized trials of calcium supplementation (<a id="xref-ref-21-1" class="xref-bibr" href="#ref-21">21</a>) and difluoromethylornithine plus sulindac for the chemoprevention of adenomas (<a id="xref-ref-22-1" class="xref-bibr" href="#ref-22">22</a>). It is advantageous that aspirin is effective for preventing advanced lesions because these lesions tend to progress more
                     rapidly to invasive cancer.
                  </p>
                  <p id="p-52">As would be expected given the endoscopic surveillance of the study populations, there were only small numbers of colorectal
                     cancers observed in the four adenoma trials. We observed no statistically significant effect of aspirin on colorectal cancer
                     occurrence. However, this apparent lack of effect does not negate the chemopreventive potential of aspirin in the large bowel.
                     The aggregate data were not powered to detect an effect on invasive colorectal cancer, and in any case, longer treatment and
                     follow-up are known to be required for such an effect to emerge (<a id="xref-ref-2-4" class="xref-bibr" href="#ref-2">2</a>,<a id="xref-ref-8-2" class="xref-bibr" href="#ref-8">8</a>).
                  </p>
                  <p id="p-53">We evaluated whether baseline factors modified the effect of aspirin in any dose. Our random-effects meta-analysis for all
                     adenomas detected no statistically significant effect modification for any of the baseline factors studied. For advanced lesions,
                     the effect of aspirin was substantially greater among those with a family history of colorectal cancer, but this result did
                     not achieve statistical significance. None of the other baseline factors studied modified the effect of aspirin on advanced
                     lesions to a statistically significant extent.
                  </p>
                  <p id="p-54">Overall, the largest benefit of aspirin (in any dose) appeared during the first year after randomization (RR = 0.62). However,
                     only one study (APACC) scheduled a protocol examination at 1 year; there were also substantial numbers of patients in CALGB
                     9270 who had early examinations. Thus, many of the examinations that occurred within 1 year from randomization were not follow-up
                     examinations prescribed by protocol. Beyond 38 months after randomization, aspirin and placebo had nearly equivalent effects
                     on the risk for all adenomas (RR = 0.99).
                  </p>
                  <p id="p-55">In the three studies that recruited adenoma patients (AFPPS, ukCAP, and APACC), participants who had an examination earlier
                     than called for by the study protocol were likely a select (and probably atypical) group of patients who might have had clinical
                     indications for the examination, such as bleeding. This selection of participants for early examination, together with the
                     smaller numbers of participants in some of the follow-up intervals, complicates interpretation of the interval-specific risk
                     ratios.
                  </p>
                  <p id="p-56">We saw no differences in the rates of adverse events comparing aspirin vs placebo in terms of mortality, myocardial infarction,
                     major bleeding, and all-site invasive cancer. However, there was a statistically significantly higher rate of strokes (most
                     of which were thought to be ischemic) among aspirin-treated participants than among those who received placebo. There is no
                     ready explanation for these findings. Aspirin use does seem to increase risk of hemorrhagic stroke modestly (<a id="xref-ref-23-1" class="xref-bibr" href="#ref-23">23</a>–<a id="xref-ref-25-1" class="xref-bibr" href="#ref-25">25</a>). However, large randomized trials that focused on cardiovascular outcomes have reported that in patients without vascular
                     disease (and who are roughly similar to participants in the adenoma trials), aspirin had no substantial effect on ischemic
                     stroke risk in men (<a id="xref-ref-23-2" class="xref-bibr" href="#ref-23">23</a>,<a id="xref-ref-24-1" class="xref-bibr" href="#ref-24">24</a>), and may reduce this risk in women (<a id="xref-ref-23-3" class="xref-bibr" href="#ref-23">23</a>).
                  </p>
                  <p id="p-57">Our meta-analysis has a number of strengths. It included all known randomized clinical trials that have tested aspirin as
                     a chemopreventive agent against colorectal adenomas. The trials were generally well conducted, with high compliance and generally
                     high follow-up rates. The sample size in the pooled studies was substantial, providing good statistical power. Thus, this
                     analysis is likely to have high validity.
                  </p>
                  <p id="p-58">However, this analysis also has substantial limitations. First, because only two studies (APACC and AFPPS) investigated lower-dose
                     aspirin, our findings regarding dose–response patterns are not as convincing as our findings regarding overall adenoma occurrence
                     and advanced-lesion occurrence. One of these two studies (APACC) was relatively small and had a substantial number of late
                     dropouts, further hampering interpretation of the aspirin dose–response relationship. Second, our analysis of cardiovascular
                     and bleeding events is quite limited. The entry criteria for the trials included the absence of a need for aspirin, which
                     is a known cardioprotective drug. This criterion assured that the study population was at relatively low risk of cardiovascular
                     events, and so the numbers of events observed in any one trial were modest. Furthermore, none of the trials focused on cardiovascular
                     disease, and the clinical detail regarding individual cardiovascular events is incomplete. Third, our exclusion of CALGB 9270
                     from the analysis of adverse events because of concerns regarding the completeness of adverse event reporting further reduced
                     the numbers of endpoints analyzed.
                  </p>
                  <p id="p-59">In summary, this meta-analysis of clinical trial data indicates that aspirin reduces the risk of recurrence of colorectal
                     adenomas. This effect emerged rather quickly after the initiation of aspirin use, seemed more marked for advanced lesions
                     than for adenomas overall, and was seen in essentially all subgroups examined. Our findings suggest that aspirin interferes
                     with colorectal carcinogenesis relatively early in the progression from normal mucosa to adenoma or advanced lesion. The substantial
                     size of the relative reduction in risk seen in our analysis (28% for advanced adenomas) and seen in clinical trials that evaluated
                     the effect of aspirin on colorectal cancer risk (26% reduction) (<a id="xref-ref-2-5" class="xref-bibr" href="#ref-2">2</a>) indicates the potentially important health benefits of aspirin use. Of course, these benefits need to be considered in the
                     context of all of the health effects of aspirin, positive and negative. As noted above, there is extensive research regarding
                     the largely positive cardiovascular effects of aspirin (<a id="xref-ref-23-4" class="xref-bibr" href="#ref-23">23</a>–<a id="xref-ref-25-2" class="xref-bibr" href="#ref-25">25</a>). The possibility of cancer prevention can now be added to future considerations of risk and benefit.
                  </p>
               </div>
               <div class="section" id="sec-25">
                  <div class="section-nav"><a href="#sec-24" title="Discussion" class="prev-section-link"><span>Previous Section</span></a><a href="#fn-group-1" title="Footnotes" class="next-section-link"><span>Next Section</span></a></div>
                  <h2>Funding</h2>
                  <p id="p-60">This study was supported by a research grant from Bayer AG to J.A. Baron.</p>
               </div>
               <div class="section fn-group" id="fn-group-1">
                  <div class="section-nav"><a href="#sec-25" title="Funding" class="prev-section-link"><span>Previous Section</span></a><a href="#ref-list-1" title="References" class="next-section-link"><span>Next Section</span></a></div>
                  <h2>Footnotes</h2>
                  <ul>
                     <li class="fn" id="fn-4">
                        <p id="p-61">The authors gratefully acknowledge the dedicated work of those who contributed to the clinical trials included in this report,
                           especially the study participants.
                        </p>
                     </li>
                     <li class="fn" id="fn-5">
                        <p id="p-62">J. A. Baron is currently a paid consultant to Bayer AG (a manufacturer of aspirin and NSAIDs) and is a former paid consultant
                           to Merck &amp; Co Inc, which marketed Vioxx, another NSAID.
                        </p>
                     </li>
                     <li class="fn" id="fn-6">
                        <p id="p-63">Research for AFPPS was supported in part by a grant from the National Cancer Institute (CA 59005) to the Polyp Prevention
                           Study Group (John A. Baron, MD, Principal Investigator). The research for Cancer and Leukemia Group B (CALGB) 9270 was supported
                           in part by grants from the National Cancer Institute (CA31946) to the Cancer and Leukemia Group B (Richard L. Schilsky, MD,
                           Chairman) and to the CALGB Statistical Center (Stephen George, PhD, CA33601).
                        </p>
                     </li>
                     <li class="fn" id="fn-7">
                        <p id="p-64">The sponsor commented on initial drafts of the protocol for the meta-analysis. The sponsor had no role in the collection,
                           analysis, or interpretation of the data, the writing of the manuscript, or the decision to submit the manuscript for publication.
                        </p>
                     </li>
                  </ul>
               </div>
               <ul>
                  <li class="fn" id="copyright-statement-1">© The Author 2009. Published by Oxford University Press.</li>
               </ul>
               <div class="section ref-list" id="ref-list-1">
                  <div class="section-nav"><a href="#fn-group-1" title="Footnotes" class="prev-section-link"><span>Previous Section</span></a><div class="nav-placeholder"> </div>
                  </div>
                  <h2>References</h2>
                  <ol class="cit-list ref-use-labels">
                     <li><span class="ref-label">1.</span><a class="rev-xref-ref" href="#xref-ref-1-1" title="View reference 1. in text"
                           id="ref-1">↵</a><div class="cit ref-cit ref-journal" id="cit-101.4.256.1">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Baron</span>  <span class="cit-name-given-names">JA</span></span></li>
                              </ol><cite>. <span class="cit-article-title">Epidemiology of non-steroidal anti-inflammatory drugs and cancer</span>. <abbr class="cit-jnl-abbrev">Prog Exp Tumor Res</abbr> <span class="cit-pub-date">2003</span>;<span class="cit-vol">37</span>:<span class="cit-fpage">1</span>-<span class="cit-lpage">24</span>.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=12795046&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=000185760800002&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a><a target="_blank"
                                 href="http://scholar.google.com/scholar_lookup?title=Epidemiology%20of%20non-steroidal%20anti-inflammatory%20drugs%20and%20cancer&amp;author=JA%20Baron&amp;publication_year=2003&amp;journal=Prog%20Exp%20Tumor%20Res&amp;volume=37&amp;pages=1-24">Google Scholar</a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">2.</span><a class="rev-xref-ref" href="#xref-ref-2-1" title="View reference 2. in text"
                           id="ref-2">↵</a><div class="cit ref-cit ref-journal" id="cit-101.4.256.2"
                             data-doi="10.1016/S0140-6736(07)60747-8">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Flossmann</span>  <span class="cit-name-given-names">E</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Rothwell</span>  <span class="cit-name-given-names">PM</span></span></li>
                              </ol><cite>. <span class="cit-article-title">Effect of aspirin on long-term risk of colorectal cancer: consistent evidence from randomised and observational studies</span>. <abbr class="cit-jnl-abbrev">Lancet</abbr> <span class="cit-pub-date">2007</span>;<span class="cit-vol">369</span>(<span class="cit-issue">9573</span>):<span class="cit-fpage">1603</span>-<span class="cit-lpage">1613</span>.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.1016/S0140-6736(07)60747-8&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=17499602&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=000246488800029&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a><a target="_blank"
                                 href="http://scholar.google.com/scholar_lookup?title=Effect%20of%20aspirin%20on%20long-term%20risk%20of%20colorectal%20cancer%3A%20consistent%20evidence%20from%20randomised%20and%20observational%20studies&amp;author=E%20Flossmann&amp;author=PM%20Rothwell&amp;publication_year=2007&amp;journal=Lancet&amp;volume=369&amp;issue=9573&amp;pages=1603-1613">Google Scholar</a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">3.</span><a class="rev-xref-ref" href="#xref-ref-3-1" title="View reference 3. in text"
                           id="ref-3">↵</a><div class="cit ref-cit ref-journal" id="cit-101.4.256.3"
                             data-doi="10.1056/NEJM199305063281805">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Giardiello</span>  <span class="cit-name-given-names">FM</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Hamilton</span>  <span class="cit-name-given-names">SR</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Krush</span>  <span class="cit-name-given-names">AJ</span></span>, 
                                 </li>
                                 <li><span class="cit-etal">et al</span></li>
                              </ol><cite>. <span class="cit-article-title">Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis</span>. <abbr class="cit-jnl-abbrev">New Engl J Med</abbr> <span class="cit-pub-date">1993</span>;<span class="cit-vol">328</span>(<span class="cit-issue">18</span>):<span class="cit-fpage">1313</span>-<span class="cit-lpage">1316</span>.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.1056/NEJM199305063281805&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=8385741&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=A1993KZ64000005&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a><a target="_blank"
                                 href="http://scholar.google.com/scholar_lookup?title=Treatment%20of%20colonic%20and%20rectal%20adenomas%20with%20sulindac%20in%20familial%20adenomatous%20polyposis&amp;author=FM%20Giardiello&amp;author=SR%20Hamilton&amp;author=AJ%20Krush&amp;publication_year=1993&amp;journal=New%20Engl%20J%20Med&amp;volume=328&amp;issue=18&amp;pages=1313-1316">Google Scholar</a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">4.</span><div class="cit ref-cit ref-journal no-rev-xref" id="cit-101.4.256.4">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Labayle</span>  <span class="cit-name-given-names">D</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Fischer</span>  <span class="cit-name-given-names">D</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Vielh</span>  <span class="cit-name-given-names">P</span></span>, 
                                 </li>
                                 <li><span class="cit-etal">et al</span></li>
                              </ol><cite>. <span class="cit-article-title">Sulindac causes regression of rectal polyps in familial adenomatous polyposis</span>. <abbr class="cit-jnl-abbrev">Gastroenterology</abbr> <span class="cit-pub-date">1991</span>;<span class="cit-vol">101</span>(<span class="cit-issue">3</span>):<span class="cit-fpage">635</span>-<span class="cit-lpage">639</span>.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=1650315&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=A1991GB05400005&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a><a target="_blank"
                                 href="http://scholar.google.com/scholar_lookup?title=Sulindac%20causes%20regression%20of%20rectal%20polyps%20in%20familial%20adenomatous%20polyposis&amp;author=D%20Labayle&amp;author=D%20Fischer&amp;author=P%20Vielh&amp;publication_year=1991&amp;journal=Gastroenterology&amp;volume=101&amp;issue=3&amp;pages=635-639">Google Scholar</a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">5.</span><div class="cit ref-cit ref-journal no-rev-xref" id="cit-101.4.256.5"
                             data-doi="10.7326/0003-4819-115-12-952">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Rigau</span>  <span class="cit-name-given-names">J</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Pique</span>  <span class="cit-name-given-names">JM</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Rubio</span>  <span class="cit-name-given-names">E</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Planas</span>  <span class="cit-name-given-names">R</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Tarrech</span>  <span class="cit-name-given-names">JM</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Bordas</span>  <span class="cit-name-given-names">JM</span></span></li>
                              </ol><cite>. <span class="cit-article-title">Effects of long-term sulindac therapy on colonic polyposis</span>. <abbr class="cit-jnl-abbrev">Ann Internal Med</abbr> <span class="cit-pub-date">1991</span>;<span class="cit-vol">115</span>(<span class="cit-issue">12</span>):<span class="cit-fpage">952</span>-<span class="cit-lpage">954</span>.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.7326/0003-4819-115-12-952&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=1659272&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=A1991GU41700007&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a><a target="_blank"
                                 href="http://scholar.google.com/scholar_lookup?title=Effects%20of%20long-term%20sulindac%20therapy%20on%20colonic%20polyposis&amp;author=J%20Rigau&amp;author=JM%20Pique&amp;author=E%20Rubio&amp;author=R%20Planas&amp;author=JM%20Tarrech&amp;author=JM%20Bordas&amp;publication_year=1991&amp;journal=Ann%20Internal%20Med&amp;volume=115&amp;issue=12&amp;pages=952-954">Google Scholar</a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">6.</span><div class="cit ref-cit ref-journal no-rev-xref" id="cit-101.4.256.6">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Higuchi</span>  <span class="cit-name-given-names">T</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Iwama</span>  <span class="cit-name-given-names">T</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Yoshinaga</span>  <span class="cit-name-given-names">K</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Toyooka</span>  <span class="cit-name-given-names">M</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Taketo</span>  <span class="cit-name-given-names">MM</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Sugihara</span>  <span class="cit-name-given-names">K</span></span></li>
                              </ol><cite>. <span class="cit-article-title">A randomized, double-blind, placebo-controlled trial of the effects of rofecoxib, a selective cyclooxygenase-2 inhibitor,
                                    on rectal polyps in familial adenomatous polyposis patients</span>. <abbr class="cit-jnl-abbrev">Clin Cancer Res</abbr> <span class="cit-pub-date">2003</span>;<span class="cit-vol">9</span>(<span class="cit-issue">13</span>):<span class="cit-fpage">4756</span>-<span class="cit-lpage">4760</span>.</cite></div>
                           <div class="cit-extra"><a href="/cgi/ijlink?linkType=ABST&amp;journalCode=clincanres&amp;resid=9/13/4756"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-ijlinks"><span class="cit-reflinks-abstract">Abstract</span><span class="cit-sep cit-reflinks-variant-name-sep">/</span><span class="cit-reflinks-full-text"><span class="free-full-text">FREE </span>Full Text</span></a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">7.</span><a class="rev-xref-ref" href="#xref-ref-7-1" title="View reference 7. in text"
                           id="ref-7">↵</a><div class="cit ref-cit ref-journal" id="cit-101.4.256.7"
                             data-doi="10.1056/NEJM200006293422603">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Steinbach</span>  <span class="cit-name-given-names">G</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Lynch</span>  <span class="cit-name-given-names">PM</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Phillips</span>  <span class="cit-name-given-names">RK</span></span>, 
                                 </li>
                                 <li><span class="cit-etal">et al</span></li>
                              </ol><cite>. <span class="cit-article-title">The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis</span>. <abbr class="cit-jnl-abbrev">New Engl J Med</abbr> <span class="cit-pub-date">2000</span>;<span class="cit-vol">342</span>(<span class="cit-issue">26</span>):<span class="cit-fpage">1946</span>-<span class="cit-lpage">1952</span>.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.1056/NEJM200006293422603&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=10874062&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=000087867400003&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a><a target="_blank"
                                 href="http://scholar.google.com/scholar_lookup?title=The%20effect%20of%20celecoxib%2C%20a%20cyclooxygenase-2%20inhibitor%2C%20in%20familial%20adenomatous%20polyposis&amp;author=G%20Steinbach&amp;author=PM%20Lynch&amp;author=RK%20Phillips&amp;publication_year=2000&amp;journal=New%20Engl%20J%20Med&amp;volume=342&amp;issue=26&amp;pages=1946-1952">Google Scholar</a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">8.</span><a class="rev-xref-ref" href="#xref-ref-8-1" title="View reference 8. in text"
                           id="ref-8">↵</a><div class="cit ref-cit ref-journal" id="cit-101.4.256.8"
                             data-doi="10.1053/j.gastro.2007.09.035">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Chan</span>  <span class="cit-name-given-names">AT</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Giovannucci</span>  <span class="cit-name-given-names">EL</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Meyerhardt</span>  <span class="cit-name-given-names">JA</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Schernhammer</span>  <span class="cit-name-given-names">ES</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Wu</span>  <span class="cit-name-given-names">K</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Fuchs</span>  <span class="cit-name-given-names">CS</span></span></li>
                              </ol><cite>. <span class="cit-article-title">Aspirin dose and duration of use and risk of colorectal cancer in men</span>. <abbr class="cit-jnl-abbrev">Gastroenterology</abbr> <span class="cit-pub-date">2008</span>;<span class="cit-vol">134</span>(<span class="cit-issue">1</span>):<span class="cit-fpage">21</span>-<span class="cit-lpage">28</span>.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.1053/j.gastro.2007.09.035&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=18005960&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=000252066400008&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a><a target="_blank"
                                 href="http://scholar.google.com/scholar_lookup?title=Aspirin%20dose%20and%20duration%20of%20use%20and%20risk%20of%20colorectal%20cancer%20in%20men&amp;author=AT%20Chan&amp;author=EL%20Giovannucci&amp;author=JA%20Meyerhardt&amp;author=ES%20Schernhammer&amp;author=K%20Wu&amp;author=CS%20Fuchs&amp;publication_year=2008&amp;journal=Gastroenterology&amp;volume=134&amp;issue=1&amp;pages=21-28">Google Scholar</a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">9.</span><a class="rev-xref-ref" href="#xref-ref-9-1" title="View reference 9. in text"
                           id="ref-9">↵</a><div class="cit ref-cit ref-journal" id="cit-101.4.256.9"
                             data-doi="10.1001/jama.294.8.914">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Chan</span>  <span class="cit-name-given-names">AT</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Giovannucci</span>  <span class="cit-name-given-names">EL</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Meyerhardt</span>  <span class="cit-name-given-names">JA</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Schernhammer</span>  <span class="cit-name-given-names">ES</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Curhan</span>  <span class="cit-name-given-names">GC</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Fuchs</span>  <span class="cit-name-given-names">CS</span></span></li>
                              </ol><cite>. <span class="cit-article-title">Long-term use of aspirin and nonsteroidal anti-inflammatory drugs and risk of colorectal cancer</span>. <abbr class="cit-jnl-abbrev">JAMA</abbr> <span class="cit-pub-date">2005</span>;<span class="cit-vol">294</span>(<span class="cit-issue">8</span>):<span class="cit-fpage">914</span>-<span class="cit-lpage">923</span>.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.1001/jama.294.8.914&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=16118381&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=000231366100021&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a><a target="_blank"
                                 href="http://scholar.google.com/scholar_lookup?title=Long-term%20use%20of%20aspirin%20and%20nonsteroidal%20anti-inflammatory%20drugs%20and%20risk%20of%20colorectal%20cancer&amp;author=AT%20Chan&amp;author=EL%20Giovannucci&amp;author=JA%20Meyerhardt&amp;author=ES%20Schernhammer&amp;author=GC%20Curhan&amp;author=CS%20Fuchs&amp;publication_year=2005&amp;journal=JAMA&amp;volume=294&amp;issue=8&amp;pages=914-923">Google Scholar</a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">10.</span><a class="rev-xref-ref" href="#xref-ref-10-1" title="View reference 10. in text"
                           id="ref-10">↵</a><div class="cit ref-cit ref-journal" id="cit-101.4.256.10"
                             data-doi="10.1056/NEJMoa021735">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Baron</span>  <span class="cit-name-given-names">JA</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Cole</span>  <span class="cit-name-given-names">BF</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Sandler</span>  <span class="cit-name-given-names">RS</span></span>, 
                                 </li>
                                 <li><span class="cit-etal">et al</span></li>
                              </ol><cite>. <span class="cit-article-title">A randomized trial of aspirin to prevent colorectal adenomas</span>. <abbr class="cit-jnl-abbrev">New Engl J Med</abbr> <span class="cit-pub-date">2003</span>;<span class="cit-vol">348</span>(<span class="cit-issue">10</span>):<span class="cit-fpage">891</span>-<span class="cit-lpage">899</span>.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.1056/NEJMoa021735&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=12621133&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=000181341100004&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a><a target="_blank"
                                 href="http://scholar.google.com/scholar_lookup?title=A%20randomized%20trial%20of%20aspirin%20to%20prevent%20colorectal%20adenomas&amp;author=JA%20Baron&amp;author=BF%20Cole&amp;author=RS%20Sandler&amp;publication_year=2003&amp;journal=New%20Engl%20J%20Med&amp;volume=348&amp;issue=10&amp;pages=891-899">Google Scholar</a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">11.</span><a class="rev-xref-ref" href="#xref-ref-11-1" title="View reference 11. in text"
                           id="ref-11">↵</a><div class="cit ref-cit ref-journal" id="cit-101.4.256.11"
                             data-doi="10.1056/NEJMoa021633">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Sandler</span>  <span class="cit-name-given-names">RS</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Halabi</span>  <span class="cit-name-given-names">S</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Baron</span>  <span class="cit-name-given-names">JA</span></span>, 
                                 </li>
                                 <li><span class="cit-etal">et al</span></li>
                              </ol><cite>. <span class="cit-article-title">A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer</span>. <abbr class="cit-jnl-abbrev">New Engl J Med</abbr> <span class="cit-pub-date">2003</span>;<span class="cit-vol">348</span>(<span class="cit-issue">10</span>):<span class="cit-fpage">883</span>-<span class="cit-lpage">890</span>.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.1056/NEJMoa021633&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=12621132&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=000181341100003&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a><a target="_blank"
                                 href="http://scholar.google.com/scholar_lookup?title=A%20randomized%20trial%20of%20aspirin%20to%20prevent%20colorectal%20adenomas%20in%20patients%20with%20previous%20colorectal%20cancer&amp;author=RS%20Sandler&amp;author=S%20Halabi&amp;author=JA%20Baron&amp;publication_year=2003&amp;journal=New%20Engl%20J%20Med&amp;volume=348&amp;issue=10&amp;pages=883-890">Google Scholar</a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">12.</span><a class="rev-xref-ref" href="#xref-ref-12-1" title="View reference 12. in text"
                           id="ref-12">↵</a><div class="cit ref-cit ref-journal" id="cit-101.4.256.12"
                             data-doi="10.1053/j.gastro.2007.10.014">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Logan</span>  <span class="cit-name-given-names">RFA</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Grainge</span>  <span class="cit-name-given-names">MJ</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Shepherd</span>  <span class="cit-name-given-names">VC</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Armitage</span>  <span class="cit-name-given-names">NC</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Muir</span>  <span class="cit-name-given-names">KR</span></span></li>
                              </ol><cite>. <span class="cit-article-title">Aspirin and folic acid for the prevention of recurrent colorectal adenomas</span>. <abbr class="cit-jnl-abbrev">Gastroenterology</abbr> <span class="cit-pub-date">2008</span>;<span class="cit-vol">134</span>(<span class="cit-issue">1</span>):<span class="cit-fpage">29</span>-<span class="cit-lpage">38</span>.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.1053/j.gastro.2007.10.014&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=18022173&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=000252066400009&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a><a target="_blank"
                                 href="http://scholar.google.com/scholar_lookup?title=Aspirin%20and%20folic%20acid%20for%20the%20prevention%20of%20recurrent%20colorectal%20adenomas&amp;author=RFA%20Logan&amp;author=MJ%20Grainge&amp;author=VC%20Shepherd&amp;author=NC%20Armitage&amp;author=KR%20Muir&amp;publication_year=2008&amp;journal=Gastroenterology&amp;volume=134&amp;issue=1&amp;pages=29-38">Google Scholar</a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">13.</span><a class="rev-xref-ref" href="#xref-ref-13-1" title="View reference 13. in text"
                           id="ref-13">↵</a><div class="cit ref-cit ref-journal" id="cit-101.4.256.13"
                             data-doi="10.1016/S0016-5085(03)00887-4">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Benamouzig</span>  <span class="cit-name-given-names">R</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Deyra</span>  <span class="cit-name-given-names">J</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Martin</span>  <span class="cit-name-given-names">A</span></span>, 
                                 </li>
                                 <li><span class="cit-etal">et al</span></li>
                              </ol><cite>. <span class="cit-article-title">Daily soluble aspirin and prevention of colorectal adenoma recurrence: one-year results of the APACC trial</span>. <abbr class="cit-jnl-abbrev">Gastroenterology</abbr> <span class="cit-pub-date">2003</span>;<span class="cit-vol">125</span>(<span class="cit-issue">2</span>):<span class="cit-fpage">328</span>-<span class="cit-lpage">336</span>.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.1016/S0016-5085(03)00887-4&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=12891533&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=000184531200010&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a><a target="_blank"
                                 href="http://scholar.google.com/scholar_lookup?title=Daily%20soluble%20aspirin%20and%20prevention%20of%20colorectal%20adenoma%20recurrence%3A%20one-year%20results%20of%20the%20APACC%20trial&amp;author=R%20Benamouzig&amp;author=J%20Deyra&amp;author=A%20Martin&amp;publication_year=2003&amp;journal=Gastroenterology&amp;volume=125&amp;issue=2&amp;pages=328-336">Google Scholar</a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">14.</span><a class="rev-xref-ref" href="#xref-ref-14-1" title="View reference 14. in text"
                           id="ref-14">↵</a><div class="cit ref-cit ref-journal" id="cit-101.4.256.14"
                             data-doi="10.1001/jama.1995.03530100085040">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Oxman</span>  <span class="cit-name-given-names">AD</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Clarke</span>  <span class="cit-name-given-names">MJ</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Stewart</span>  <span class="cit-name-given-names">LA</span></span></li>
                              </ol><cite>. <span class="cit-article-title">From science to practice. Meta-analyses using individual patient data are needed</span>. <abbr class="cit-jnl-abbrev">JAMA</abbr> <span class="cit-pub-date">1995</span>;<span class="cit-vol">274</span>(<span class="cit-issue">10</span>):<span class="cit-fpage">845</span>-<span class="cit-lpage">846</span>.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.1001/jama.1995.03530100085040&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=7650811&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=A1995RU32400035&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a><a target="_blank"
                                 href="http://scholar.google.com/scholar_lookup?title=From%20science%20to%20practice.%20Meta-analyses%20using%20individual%20patient%20data%20are%20needed&amp;author=AD%20Oxman&amp;author=MJ%20Clarke&amp;author=LA%20Stewart&amp;publication_year=1995&amp;journal=JAMA&amp;volume=274&amp;issue=10&amp;pages=845-846">Google Scholar</a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">15.</span><a class="rev-xref-ref" href="#xref-ref-15-1" title="View reference 15. in text"
                           id="ref-15">↵</a><div class="cit ref-cit ref-journal" id="cit-101.4.256.15"
                             data-doi="10.1016/0197-2456(86)90046-2">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">DerSimonian</span>  <span class="cit-name-given-names">R</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Laird</span>  <span class="cit-name-given-names">N</span></span></li>
                              </ol><cite>. <span class="cit-article-title">Meta-analysis in clinical trials</span>. <abbr class="cit-jnl-abbrev">Control Clin Trials</abbr> <span class="cit-pub-date">1986</span>;<span class="cit-vol">7</span>(<span class="cit-issue">15</span>):<span class="cit-fpage">177</span>-<span class="cit-lpage">188</span>.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.1016/0197-2456(86)90046-2&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=3802833&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=A1986F013900001&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a><a target="_blank"
                                 href="http://scholar.google.com/scholar_lookup?title=Meta-analysis%20in%20clinical%20trials&amp;author=R%20DerSimonian&amp;author=N%20Laird&amp;publication_year=1986&amp;journal=Control%20Clin%20Trials&amp;volume=7&amp;issue=15&amp;pages=177-188">Google Scholar</a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">16.</span><div class="cit ref-cit ref-journal no-rev-xref" id="cit-101.4.256.16"
                             data-doi="10.1136/bmj.315.7121.1533">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Egger</span>  <span class="cit-name-given-names">M</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Smith</span>  <span class="cit-name-given-names">GD</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Phillips</span>  <span class="cit-name-given-names">AN</span></span></li>
                              </ol><cite>. <span class="cit-article-title">Meta-analysis: principles and procedures</span>. <abbr class="cit-jnl-abbrev">BMJ</abbr> <span class="cit-pub-date">1997</span>;<span class="cit-vol">315</span>(<span class="cit-issue">7121</span>):<span class="cit-fpage">1533</span>-<span class="cit-lpage">1537</span>.</cite></div>
                           <div class="cit-extra"><a href="/cgi/ijlink?linkType=FULL&amp;journalCode=bmj&amp;resid=315/7121/1533"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-ijlinks"><span class="cit-reflinks-full-text"><span class="free-full-text">FREE </span>Full Text</span></a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">17.</span><a class="rev-xref-ref" href="#xref-ref-17-1" title="View reference 17. in text"
                           id="ref-17">↵</a><div class="cit ref-cit ref-book" id="cit-101.4.256.17">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Friedman</span>  <span class="cit-name-given-names">LM</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Furberg</span>  <span class="cit-name-given-names">CD</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">DeMets</span>  <span class="cit-name-given-names">DL</span></span></li>
                              </ol><cite>. <span class="cit-source">Fundamentals of Clinical Trials</span>. <span class="cit-publ-loc">New York</span>: <span class="cit-publ-name">Springer</span>; <span class="cit-pub-date">1998</span>.</cite></div>
                           <div class="cit-extra"><a target="_blank"
                                 href="http://scholar.google.com/scholar_lookup?title=Fundamentals%20of%20Clinical%20Trials&amp;author=LM%20Friedman&amp;author=CD%20Furberg&amp;author=DL%20DeMets&amp;publication_year=1998">Google Scholar</a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">18.</span><a class="rev-xref-ref" href="#xref-ref-18-1" title="View reference 18. in text"
                           id="ref-18">↵</a><div class="cit ref-cit ref-journal" id="cit-101.4.256.18"
                             data-doi="10.1002/sim.1188">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Deeks</span>  <span class="cit-name-given-names">JJ</span></span></li>
                              </ol><cite>. <span class="cit-article-title">Issues in the selection of a summary statistic for meta-analysis of clinical trials with binary outcomes</span>. <abbr class="cit-jnl-abbrev">Stat Med</abbr> <span class="cit-pub-date">2002</span>;<span class="cit-vol">21</span>(<span class="cit-issue">11</span>):<span class="cit-fpage">1575</span>-<span class="cit-lpage">1600</span>.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.1002/sim.1188&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=12111921&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=000176016900007&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a><a target="_blank"
                                 href="http://scholar.google.com/scholar_lookup?title=Issues%20in%20the%20selection%20of%20a%20summary%20statistic%20for%20meta-analysis%20of%20clinical%20trials%20with%20binary%20outcomes&amp;author=JJ%20Deeks&amp;publication_year=2002&amp;journal=Stat%20Med&amp;volume=21&amp;issue=11&amp;pages=1575-1600">Google Scholar</a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">19.</span><a class="rev-xref-ref" href="#xref-ref-19-1" title="View reference 19. in text"
                           id="ref-19">↵</a><div class="cit ref-cit ref-journal" id="cit-101.4.256.19"
                             data-doi="10.1136/bmj.327.7414.557">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Higgins</span>  <span class="cit-name-given-names">JP</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Thompson</span>  <span class="cit-name-given-names">SG</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Deeks</span>  <span class="cit-name-given-names">JJ</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Altman</span>  <span class="cit-name-given-names">DG</span></span></li>
                              </ol><cite>. <span class="cit-article-title">Measuring inconsistency in meta-analyses</span>. <abbr class="cit-jnl-abbrev">BMJ</abbr> <span class="cit-pub-date">2003</span>;<span class="cit-vol">327</span>(<span class="cit-issue">7414</span>):<span class="cit-fpage">557</span>-<span class="cit-lpage">560</span>.</cite></div>
                           <div class="cit-extra"><a href="/cgi/ijlink?linkType=FULL&amp;journalCode=bmj&amp;resid=327/7414/557"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-ijlinks"><span class="cit-reflinks-full-text"><span class="free-full-text">FREE </span>Full Text</span></a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">20.</span><a class="rev-xref-ref" href="#xref-ref-20-1" title="View reference 20. in text"
                           id="ref-20">↵</a><div class="cit ref-cit ref-journal" id="cit-101.4.256.20">
                           <div class="cit-metadata"><cite><span class="cit-auth cit-collab">Expert Panel on the Identification EvaluationTreatment of Overweight in Adults</span>. <span class="cit-article-title">Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults: executive summary</span>. <abbr class="cit-jnl-abbrev">Am J Clin Nutr</abbr> <span class="cit-pub-date">1998</span>;<span class="cit-vol">68</span>(<span class="cit-issue">4</span>):<span class="cit-fpage">899</span>-<span class="cit-lpage">917</span>.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=9771869&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=000076192600021&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">21.</span><a class="rev-xref-ref" href="#xref-ref-21-1" title="View reference 21. in text"
                           id="ref-21">↵</a><div class="cit ref-cit ref-journal" id="cit-101.4.256.21"
                             data-doi="10.1093/jnci/djh165">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Wallace</span>  <span class="cit-name-given-names">K</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Baron</span>  <span class="cit-name-given-names">JA</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Cole</span>  <span class="cit-name-given-names">BF</span></span>, 
                                 </li>
                                 <li><span class="cit-etal">et al</span></li>
                              </ol><cite>. <span class="cit-article-title">Effect of calcium supplementation on the risk of large bowel polyps</span>. <abbr class="cit-jnl-abbrev">J Natl Cancer Inst</abbr> <span class="cit-pub-date">2004</span>;<span class="cit-vol">96</span>(<span class="cit-issue">12</span>):<span class="cit-fpage">921</span>-<span class="cit-lpage">925</span>.</cite></div>
                           <div class="cit-extra"><a href="/cgi/ijlink?linkType=ABST&amp;journalCode=jnci&amp;resid=96/12/921"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-ijlinks"><span class="cit-reflinks-abstract">Abstract</span><span class="cit-sep cit-reflinks-variant-name-sep">/</span><span class="cit-reflinks-full-text"><span class="free-full-text">FREE </span>Full Text</span></a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">22.</span><a class="rev-xref-ref" href="#xref-ref-22-1" title="View reference 22. in text"
                           id="ref-22">↵</a><div class="cit ref-cit ref-journal" id="cit-101.4.256.22"
                             data-doi="10.1158/1940-6207.CAPR-08-0042">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Meyskens</span>  <span class="cit-name-given-names">FL</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">McLaren</span>  <span class="cit-name-given-names">CE</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Pelot</span>  <span class="cit-name-given-names">D</span></span>, 
                                 </li>
                                 <li><span class="cit-etal">et al</span></li>
                              </ol><cite>. <span class="cit-article-title">Difluoromethylornithine plus sulindac for the prevention of sporadic colorectal adenomas: a randomized placebo-controlled,
                                    double-blind trial</span>. <abbr class="cit-jnl-abbrev">Cancer Prevent Res</abbr> <span class="cit-pub-date">2008</span>;<span class="cit-vol">1</span>(<span class="cit-issue">1</span>):<span class="cit-fpage">32</span>-<span class="cit-lpage">38</span>.</cite></div>
                           <div class="cit-extra"><a href="/cgi/ijlink?linkType=ABST&amp;journalCode=canprevres&amp;resid=1/1/32"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-ijlinks"><span class="cit-reflinks-abstract">Abstract</span><span class="cit-sep cit-reflinks-variant-name-sep">/</span><span class="cit-reflinks-full-text"><span class="free-full-text">FREE </span>Full Text</span></a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">23.</span><a class="rev-xref-ref" href="#xref-ref-23-1" title="View reference 23. in text"
                           id="ref-23">↵</a><div class="cit ref-cit ref-journal" id="cit-101.4.256.23"
                             data-doi="10.1001/jama.295.3.306">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Berger</span>  <span class="cit-name-given-names">JS</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Roncaglioni</span>  <span class="cit-name-given-names">MC</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Avanzini</span>  <span class="cit-name-given-names">F</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Pangrazzi</span>  <span class="cit-name-given-names">I</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Tognoni</span>  <span class="cit-name-given-names">G</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Brown</span>  <span class="cit-name-given-names">DL</span></span></li>
                              </ol><cite>. <span class="cit-article-title">Aspirin for the primary prevention of cardiovascular events in women and men: a sex-specific meta-analysis of randomized controlled
                                    trials</span>. <abbr class="cit-jnl-abbrev">JAMA</abbr> <span class="cit-pub-date">2006</span>;<span class="cit-vol">295</span>(<span class="cit-issue">3</span>):<span class="cit-fpage">306</span>-<span class="cit-lpage">313</span>.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.1001/jama.295.3.306&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=16418466&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=000234684500024&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a><a target="_blank"
                                 href="http://scholar.google.com/scholar_lookup?title=Aspirin%20for%20the%20primary%20prevention%20of%20cardiovascular%20events%20in%20women%20and%20men%3A%20a%20sex-specific%20meta-analysis%20of%20randomized%20controlled%20trials&amp;author=JS%20Berger&amp;author=MC%20Roncaglioni&amp;author=F%20Avanzini&amp;author=I%20Pangrazzi&amp;author=G%20Tognoni&amp;author=DL%20Brown&amp;publication_year=2006&amp;journal=JAMA&amp;volume=295&amp;issue=3&amp;pages=306-313">Google Scholar</a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">24.</span><a class="rev-xref-ref" href="#xref-ref-24-1" title="View reference 24. in text"
                           id="ref-24">↵</a><div class="cit ref-cit ref-journal" id="cit-101.4.256.24"
                             data-doi="10.1001/archinte.163.17.2006">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Eidelman</span>  <span class="cit-name-given-names">RS</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Hebert</span>  <span class="cit-name-given-names">PR</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Weisman</span>  <span class="cit-name-given-names">SM</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Hennekens</span>  <span class="cit-name-given-names">CH</span></span></li>
                              </ol><cite>. <span class="cit-article-title">An update on aspirin in the primary prevention of cardiovascular disease</span>. <abbr class="cit-jnl-abbrev">Arch Intern Med</abbr> <span class="cit-pub-date">2003</span>;<span class="cit-vol">163</span>(<span class="cit-issue">17</span>):<span class="cit-fpage">2006</span>-<span class="cit-lpage">2010</span>.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.1001/archinte.163.17.2006&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=14504112&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=000185490800002&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a><a target="_blank"
                                 href="http://scholar.google.com/scholar_lookup?title=An%20update%20on%20aspirin%20in%20the%20primary%20prevention%20of%20cardiovascular%20disease&amp;author=RS%20Eidelman&amp;author=PR%20Hebert&amp;author=SM%20Weisman&amp;author=CH%20Hennekens&amp;publication_year=2003&amp;journal=Arch%20Intern%20Med&amp;volume=163&amp;issue=17&amp;pages=2006-2010">Google Scholar</a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">25.</span><a class="rev-xref-ref" href="#xref-ref-25-1" title="View reference 25. in text"
                           id="ref-25">↵</a><div class="cit ref-cit ref-journal" id="cit-101.4.256.25"
                             data-doi="10.1001/jama.280.22.1930">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">He</span>  <span class="cit-name-given-names">J</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Whelton</span>  <span class="cit-name-given-names">PK</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Vu</span>  <span class="cit-name-given-names">B</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Klag</span>  <span class="cit-name-given-names">MJ</span></span></li>
                              </ol><cite>. <span class="cit-article-title">Aspirin and risk of hemorrhagic stroke: a meta-analysis of randomized controlled trials</span>. <abbr class="cit-jnl-abbrev">JAMA</abbr> <span class="cit-pub-date">1998</span>;<span class="cit-vol">280</span>(<span class="cit-issue">22</span>):<span class="cit-fpage">1930</span>-<span class="cit-lpage">1935</span>.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.1001/jama.280.22.1930&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=9851479&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=000077364500038&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a><a target="_blank"
                                 href="http://scholar.google.com/scholar_lookup?title=Aspirin%20and%20risk%20of%20hemorrhagic%20stroke%3A%20a%20meta-analysis%20of%20randomized%20controlled%20trials&amp;author=J%20He&amp;author=PK%20Whelton&amp;author=B%20Vu&amp;author=MJ%20Klag&amp;publication_year=1998&amp;journal=JAMA&amp;volume=280&amp;issue=22&amp;pages=1930-1935">Google Scholar</a></div>
                        </div>
                     </li>
                  </ol>
               </div><span class="highwire-journal-article-marker-end"></span></div>
            <div id="related">
               <h2>Related articles</h2>
               <ul class="related-list">
                  <div class="cit">
                     <div class="cit-metadata"><span class="cit-first-element cit-section">IN THIS ISSUE<span class="cit-sep cit-sep-after-article-section">:</span> </span><span class="cit-title">IN THIS ISSUE </span> <cite><abbr title="Journal of the National Cancer Institute" class="site-title">JNCI J Natl Cancer Inst</abbr> <span class="cit-print-date"><span class="cit-sep cit-sep-before-article-print-date">(</span>2009<span class="cit-sep cit-sep-after-article-print-date">)</span> </span><span class="cit-vol">101 </span><span class="cit-issue"><span class="cit-sep cit-sep-before-article-issue">(</span>4<span class="cit-sep cit-sep-after-article-issue">):</span> </span><span class="cit-pages"><span class="cit-first-page">215</span> </span><span class="cit-doi"><span class="cit-sep cit-sep-before-article-doi"> doi:</span>10.1093/jnci/djp010 </span><span class="cit-online-date"><span class="cit-sep cit-sep-before-article-online-date">First published online </span>February 17, 2009 </span></cite>  
                     </div>
                     <div class="cit-extra"><span class="accesscheck jnci;101/4/215 pdf_extract,full,reprint"></span> 
                        <ul class="cit-views">
                           <li class="first-item"><a href="/content/101/4/215.1.extract" rel="extract">Extract</a></li>
                           <li><a href="/content/101/4/215.1.full" rel="full-text">Full Text (HTML)</a></li>
                           <li class="last-item"><a href="/content/101/4/215.1.full.pdf+html" rel="full-text.pdf">Full Text (PDF)</a></li>
                        </ul>  
                     </div> 
                  </div>
               </ul>
            </div><span id="related-urls"></span></div>
         <div id="col-2">
            
            <div class="article-nav sidebar-nav">
               <a href="/content/101/4/248.short" title="Previous article" class="previous">« Previous</a><span class="article-nav-sep"> | </span><a href="/content/101/4/267.short" title="Next article" class="next">Next Article »</a>
               
               <span class="toc-link">
                  				<a href="/content/101/4.toc" title="Table of Contents">Table of Contents</a>
                  			</span>
               
               
            </div>
            <div class="content-box" id="article-cb-main">
               <div class="cb-contents">
                  <h3 class="cb-contents-header"><span>This Article</span></h3>
                  <div class="cb-section cb-slug">
                     <ol>
                        <li>
                           <div id="slugline">
                              
                              <cite>
                                 <abbr title="JNCI Journal of the National Cancer Institute" class="slug-jnl-abbrev">
                                    <nlm:abbrev-journal-title xmlns:nlm="http://schema.highwire.org/NLM/Journal" abbrev-type="publisher">JNCI J Natl Cancer Inst</nlm:abbrev-journal-title></abbr><span class="slug-pub-date" itemprop="datePublished">
                                    (2009) 
                                    </span>
                                 
                                 <span class="slug-vol">
                                    101
                                    </span><span class="slug-issue">
                                    (4):
                                    </span><span class="slug-pages">
                                    256-266.
                                    </span>
                                 <span class="slug-doi-wrapper">
                                    
                                    doi:
                                    
                                    <span title="10.1093/jnci/djn485" class="slug-doi">10.1093/jnci/djn485</span>
                                    </span>
                                 </cite>
                              
                              
                              <span class="slug-metadata-note ahead-of-print">
                                 
                                 First published online
                                 
                                 <span class="slug-ahead-of-print-date">February 10, 2009</span>
                                 </span>
                              
                              
                              
                              
                              
                              
                              
                              
                              
                           </div>
                        </li>
                     </ol>
                  </div>
                  <div class="cb-section cb-views">
                     <ol>
                        <li class="abstract-view-link primary"><a href="/content/101/4/256.abstract" rel="view-abstract">Abstract</a><span class="free">Free</span></li>
                        <li class="notice full-text-view-link"><span class="variant-indicator">» <span>Full Text (HTML)</span></span><span class="free">Free</span></li>
                        <li class="notice full-text-pdf-view-link"><a href="/content/101/4/256.full.pdf+html" rel="view-full-text.pdf">Full Text (PDF)</a><span class="free">Free</span></li>
                        <li><a href="/content/101/4/256/suppl/DC1" rel="supplemental-data"
                              class="dslink-supplementary-data">Supplementary Data</a></li>
                        <li class="cb-versions">
                           <div><span id="pap-all-versions-label">All Versions of this Article:</span><ol class="version-list">
                                 <li><a href="/content/early/2009/02/10/jnci.djn485">djn485v1</a></li>
                                 <li class="current-li"><span>101/4/256</span> <span class="current-version">most recent</span></li>
                              </ol>
                           </div>
                        </li>
                     </ol>
                  </div>
                  <div class="cb-section collapsible" id="cb-art-cat">
                     <h4 class="cb-section-header"><span>Classifications</span></h4>
                     <ol>
                        <li>
                           <ul class="subject-headings last-child">
                              <li><a class="tocsection-search"
                                    href="/search?tocsectionid=ARTICLES&amp;sortspec=date&amp;submit=Submit">Article</a></li>
                           </ul>
                        </li>
                     </ol>
                  </div>
                  <div class="cb-section collapsible" id="cb-art-svcs">
                     <h4 class="cb-section-header"><span>Services</span></h4>
                     <ol>
                        <li class="usage-stats-link icon-link"><a href="/articleusage?gca=jnci;101/4/256" rel="nofollow">Article metrics</a></li>
                        <li class="alert-link icon-link"><a href="/cgi/alerts/ctalert?alertType=citedby&amp;addAlert=cited_by&amp;cited_by_criteria_resid=jnci%3B101%2F4%2F256&amp;saveAlert=no&amp;return-type=article&amp;return_url=http://jnci.oxfordjournals.org/content/101/4/256.full">Alert me when cited</a></li>
                        <li class="alert-link icon-link"><a href="/cgi/alerts/ctalert?alertType=correction&amp;addAlert=correction&amp;correction_criteria_value=101/4/256&amp;saveAlert=no&amp;return-type=article&amp;return_url=http://jnci.oxfordjournals.org/content/101/4/256.full">Alert me if corrected</a></li>
                        <li class="similar-link"><a href="/search?qbe=jnci%3Bdjn485&amp;citation=Cole%20et%20al.%20101%20%284%29:%20256&amp;submit=yes">Find similar articles</a></li>
                        <li class="similar-link"><a href="/external-ref?access_num=jnci%3B101%2F4%2F256&amp;link_type=ISI_RELATEDRECORDS"
                              id="cb-isi-similar-articles"
                              class="similar-link">Similar articles in Web of Science</a></li>
                        <li class="similar-link"><a href="/external-ref?access_num=19211452&amp;link_type=MED_NBRS"
                              class="similar-link">Similar articles in PubMed</a></li>
                        <li class="folder-link icon-link"><a href="/cgi/folders?action=addtofolder&amp;wherefrom=JOURNALS&amp;wrapped_id=jnci%3B101%2F4%2F256">Add to my archive</a></li>
                        <li class="cit-man-link icon-link cite-link"><a href="/citmgr?gca=jnci%3B101%2F4%2F256">Download citation</a></li>
                        <li><a class="request-permissions"
                              href="https://s100.copyright.com/AppDispatchServlet?publisherName=oup&amp;publication=jnci&amp;title=Aspirin%20for%20the%20Chemoprevention%20of%20Colorectal%20Adenomas%3A%20Meta-analysis%20of%20the%20Randomized%20Trials%3A%20&amp;publicationDate=02%2F18%2F2009&amp;author=Bernard%20F.%20Cole%2C%20Richard%20F.%20Logan%2C%20Susan%20Halabi%2C%20Robert%20Benamouzig%2C%20Robert%20S.%20Sandler%2C%20Matthew%20J.%20Grainge%2C%20Stanislas%20Chaussade%2C%20John%20A.%20Baron&amp;copyright=Oxford%20University%20Press&amp;contentID=10.1093%2Fjnci%2Fdjn485&amp;volumeNum=101&amp;issueNum=4&amp;startPage=256&amp;endPage=266&amp;orderBeanReset=true"
                              target="_blank">Request Permissions</a></li>
                     </ol>
                  </div>
                  <div class="cb-section collapsible default-closed" id="cb-art-cit">
                     <h4 class="cb-section-header"><span>Citing Articles</span></h4>
                     <ol>
                        <li class="hw-citing-link"><a href="/content/101/4/256.full?cited-by=yes&amp;legid=jnci;101/4/256#cited-by"
                              id="cb-hw-citing-articles">Load citing article information</a></li>
                        <li><a href="/cgi/crossref-forward-links/101/4/256" rel="external-nw"
                              id="cb-crossref-citing-articles">Citing articles via CrossRef</a></li>
                        <li><a href="/scopus-links/jnci/101/4/256?access_num=/jnci/101/4/256"
                              rel="external-nw"
                              id="cb-scopus-citing-articles">Citing articles via Scopus</a></li>
                        <li><a href="/external-ref?access_num=%2Fjnci%2F101%2F4%2F256&amp;link_type=ISI_CITING&amp;accnum_type=native"
                              rel="external-nw"
                              id="cb-isi-citing-articles">Citing articles via Web of Science</a></li>
                        <li><a href="/external-ref?access_num=http://jnci.oxfordjournals.org/content/101/4/256.abstract&amp;link_type=GOOGLESCHOLAR">Citing articles via Google Scholar</a></li>
                     </ol>
                  </div>
                  <div class="cb-section collapsible default-closed" id="cb-art-gs">
                     <h4 class="cb-section-header"><span>Google Scholar</span></h4>
                     <ol>
                        <li class="cb-art-gs-auth author-link"><a href="http://scholar.google.com/scholar?q=%22author%3ACole%20author%3AB.F.%22"
                              class="cb-art-gs-auth author-link">Articles by  Cole, B. F.</a></li>
                        <li class="cb-art-gs-auth author-link"><a href="http://scholar.google.com/scholar?q=%22author%3ABaron%20author%3AJ.A.%22"
                              class="cb-art-gs-auth author-link">Articles by  Baron, J. A.</a></li>
                        <li class="cb-art-gs-rel similar-link"><a href="/external-ref?access_num=http://jnci.oxfordjournals.org/content/101/4/256.abstract&amp;link_type=GOOGLESCHOLARRELATED">Search for related content</a></li>
                     </ol>
                  </div>
                  <div class="cb-section collapsible default-closed" id="cb-art-pm">
                     <h4 class="cb-section-header"><span>PubMed</span></h4>
                     <ol>
                        <li class="cb-art-pm-cite cite-link icon-link"><a href="/external-ref?access_num=19211452&amp;link_type=PUBMED"
                              class="cb-art-pm-cite cite-link icon-link">PubMed citation</a></li>
                        <li class="cb-art-pm-auth author-link"><a href="/external-ref?access_num=Cole%20BF&amp;link_type=AUTHORSEARCH"
                              class="cb-art-pm-auth author-link">Articles by  Cole, B. F.</a></li>
                        <li class="cb-art-pm-auth author-link"><a href="/external-ref?access_num=Logan%20RF&amp;link_type=AUTHORSEARCH"
                              class="cb-art-pm-auth author-link">Articles by  Logan, R. F.</a></li>
                        <li class="cb-art-pm-auth author-link"><a href="/external-ref?access_num=Halabi%20S&amp;link_type=AUTHORSEARCH"
                              class="cb-art-pm-auth author-link">Articles by  Halabi, S.</a></li>
                        <li class="cb-art-pm-auth author-link"><a href="/external-ref?access_num=Benamouzig%20R&amp;link_type=AUTHORSEARCH"
                              class="cb-art-pm-auth author-link">Articles by  Benamouzig, R.</a></li>
                        <li class="cb-art-pm-auth author-link"><a href="/external-ref?access_num=Sandler%20RS&amp;link_type=AUTHORSEARCH"
                              class="cb-art-pm-auth author-link">Articles by  Sandler, R. S.</a></li>
                        <li class="cb-art-pm-auth author-link"><a href="/external-ref?access_num=Grainge%20MJ&amp;link_type=AUTHORSEARCH"
                              class="cb-art-pm-auth author-link">Articles by  Grainge, M. J.</a></li>
                        <li class="cb-art-pm-auth author-link"><a href="/external-ref?access_num=Chaussade%20S&amp;link_type=AUTHORSEARCH"
                              class="cb-art-pm-auth author-link">Articles by  Chaussade, S.</a></li>
                        <li class="cb-art-pm-auth author-link"><a href="/external-ref?access_num=Baron%20JA&amp;link_type=AUTHORSEARCH"
                              class="cb-art-pm-auth author-link">Articles by  Baron, J. A.</a></li>
                     </ol>
                  </div>
                  <div class="cb-section collapsible default-closed" id="cb-art-rel">
                     <h4 class="cb-section-header"><span>Related Content</span></h4>
                     <ol>
                        <li><a href="#related">Related articles in this journal</a></li>
                        <li><a href="/content/101/4/256.full?related-urls=yes&amp;legid=jnci;101/4/256#related-urls"
                              id="cb-related-urls">Load related web page information</a></li>
                     </ol>
                  </div>
                  <div class="cb-section collapsible" id="cb-art-soc">
                     <h4 class="cb-section-header"><span>Share</span></h4>
                     <ol>
                        <li><a href="/email?gca=jnci%3B101%2F4%2F256&amp;current-view-path=/content/101/4/256.full">
                              Email this article</a></li>
                        <li>
                           <div class="social-bookmarking">
                              
                              <ul class="social-bookmark-links">
                                 <li class="social-bookmarking-item social-bookmarking-item-citeulike"><a href="/external-ref?tag_url=http://jnci.oxfordjournals.org/cgi/content/long/101/4/256&amp;title=Aspirin%20for%20the%20Chemoprevention%20of%20Colorectal%20Adenomas%3A%20Meta-analysis%20of%20the%20Randomized%20Trials+--+Cole%20et%20al.%20101%20%284%29%3A%20256+--+jnci&amp;doi=10.1093/jnci/djn485&amp;link_type=CITEULIKE"><img src="/shared/img/common/social-bookmarking/citeulike.gif"
                                            alt="Add to CiteULike"
                                            title="CiteULike" /></a><span class="soc-bm-link-text">CiteULike</span></li>
                                 <li class="social-bookmarking-item social-bookmarking-item-delicious"><a href="/external-ref?tag_url=http://jnci.oxfordjournals.org/cgi/content/long/101/4/256&amp;title=Aspirin%20for%20the%20Chemoprevention%20of%20Colorectal%20Adenomas%3A%20Meta-analysis%20of%20the%20Randomized%20Trials+--+Cole%20et%20al.%20101%20%284%29%3A%20256+--+jnci&amp;doi=10.1093/jnci/djn485&amp;link_type=DEL_ICIO_US"><img src="/shared/img/common/social-bookmarking/delicious.gif"
                                            alt="Add to Delicious"
                                            title="Delicious" /></a><span class="soc-bm-link-text">Delicious</span></li>
                                 <li class="social-bookmarking-item social-bookmarking-item-facebook"><a href="/external-ref?tag_url=http://jnci.oxfordjournals.org/cgi/content/short/101/4/256&amp;title=Aspirin%20for%20the%20Chemoprevention%20of%20Colorectal%20Adenomas%3A%20Meta-analysis%20of%20the%20Randomized%20Trials+--+Cole%20et%20al.%20101%20%284%29%3A%20256+--+jnci&amp;doi=10.1093/jnci/djn485&amp;link_type=FACEBOOK"
                                       class="sb-facebook"
                                       rel="external-nw"><img src="/shared/img/common/social-bookmarking/facebook.gif" alt="Add to Facebook"
                                            title="Facebook" /></a><span class="soc-bm-link-text">Facebook</span></li>
                                 <li class="social-bookmarking-item social-bookmarking-item-googleplus"><a href="/external-ref?tag_url=http://jnci.oxfordjournals.org/cgi/content/long/101/4/256&amp;title=Aspirin%20for%20the%20Chemoprevention%20of%20Colorectal%20Adenomas%3A%20Meta-analysis%20of%20the%20Randomized%20Trials+--+Cole%20et%20al.%20101%20%284%29%3A%20256+--+jnci&amp;doi=10.1093/jnci/djn485&amp;link_type=GOOGLEPLUS&amp;log_only=yes"><img src="/shared/img/common/social-bookmarking/googleplus.jpg" alt="Add to Google+"
                                            title="Google+" /></a><span class="soc-bm-link-text">Google+</span></li>
                                 <li class="social-bookmarking-item social-bookmarking-item-mendeley"><a href="/external-ref?tag_url=http://jnci.oxfordjournals.org/cgi/content/long/101/4/256&amp;title=Aspirin%20for%20the%20Chemoprevention%20of%20Colorectal%20Adenomas%3A%20Meta-analysis%20of%20the%20Randomized%20Trials+--+Cole%20et%20al.%20101%20%284%29%3A%20256+--+jnci&amp;doi=10.1093/jnci/djn485&amp;link_type=MENDELEY"><img src="/shared/img/common/social-bookmarking/mendeley.gif" alt="Add to Mendeley"
                                            title="Mendeley" /></a><span class="soc-bm-link-text">Mendeley</span></li>
                                 <li class="social-bookmarking-item social-bookmarking-item-twitter"><a href="/external-ref?tag_url=http://jnci.oxfordjournals.org/cgi/content/long/101/4/256&amp;title=Aspirin%20for%20the%20Chemoprevention%20of%20Colorectal%20Adenomas%3A%20Meta-analysis%20of%20the%20Randomized%20Trials+--+Cole%20et%20al.%20101%20%284%29%3A%20256+--+jnci&amp;doi=10.1093/jnci/djn485&amp;link_type=TWITTER"><img src="/shared/img/common/social-bookmarking/twitter.gif" alt="Add to Twitter"
                                            title="Twitter" /></a><span class="soc-bm-link-text">Twitter</span></li>
                              </ul>
                              
                              <p class="social-bookmarking-help"><a href="/help/social_bookmarks.dtl">What's this?</a></p>
                              
                           </div>
                        </li>
                     </ol>
                  </div>
               </div>
            </div>
            
            
            <div class="content-box" id="article-dyn-nav">
               <div class="cb-contents">
                  <h3 class="cb-contents-header"><span>Navigate This Article</span></h3>
                  <div class="cb-section" id="cb-art-nav">
                     <ol>
                        <li><a href="#content-block">Top</a></li>
                        <li><a href="#abstract-1">Abstract</a></li>
                        <li><a href="#sec-11">Methods</a></li>
                        <li><a href="#sec-15">Results</a></li>
                        <li><a href="#sec-24">Discussion</a></li>
                        <li><a href="#sec-25">Funding</a></li>
                        <li><a href="#fn-group-1">Footnotes</a></li>
                        <li><a href="#ref-list-1">References</a></li>
                     </ol>
                  </div>
               </div>
            </div>
            
         </div>
         <div id="col-3">
            
            <div id="col-3-qs" class="sidebar-qs">
               
               
               <form class="searchbox" action="/search" method="get">
                  <p>Search this journal:</p>
                  <div>
                     	
                     	
                     	<input value="" type="text" name="fulltext" id="header-qs-input" />
                     <input type="hidden" name="submit" value="yes" />
                     
                     <input class="inline_button" type="image" alt="Go" src="/publisher/img/buttons/go.gif" />
                     
                     <div class="adv-search-link"><a href="/search">Advanced »</a></div>
                     
                     
                  </div>
               </form>
               
            </div>
            <div class="cb-contents">
               
               <div id="sidebar-current-issue" class="content-box">
                  	
                  <h3 class="cb-contents-header">Current Issue</h3>
                  	
                  <div class="cb-section">
                     	  
                     <ol>
                        <li>
                           	      <a href="/content/current"><span>
                                 		  <span class="current-issue-date">
                                    October 2015
                                    </span><span class="toc-citation-volume">
                                    
                                    107
                                    </span><span class="toc-citation-issue">(10)</span>
                                 		  
                                 		</span></a>
                           	    
                        </li>
                     </ol>
                     	
                  </div>
                  	
                  <div class="cb-section">
                     	  
                     <ol>
                        <li>
                           <a href="/content/current"><img src="/content/107/10.cover.gif" alt="JNCI J Natl Cancer Inst" id="cover" /></a>
                           
                        </li>
                     </ol>
                     	
                  </div>
                  	
                  <div class="cb-section sidebar-etoc-link">
                     	  
                     <ol>
                        <li><a href="/cgi/alerts/etoc">Alert me to new issues</a></li>
                     </ol>
                     	
                  </div>
                  
               </div>
               
            </div>
            
            <div id="second">
               
               <div class="ad_hidden" id="oas_right1">
                  <iframe id="id_advertframe_right1"
                          src="/resource/htmlfiles/advert.html?p=Right1&amp;u=jnci.oxfordjournals.org/content/101/4/256.full"
                          width="0"
                          height="0"
                          frameborder="0"
                          scrolling="no"
                          class="resize_ad"></iframe>
                  
               </div>
               
               <div class="features">
                  
                  <div class="feature separator_after first">
                     
                     <h2 id="the_journal" title="The Journal"><span>The Journal</span></h2>
                     
                     <ul class="emphasised">
                        <li>
                           <a href="http://www.oxfordjournals.org/our_journals/jnci/about.html" rel=""
                              title="About this journal">About this journal</a>
                           
                        </li>
                        <li>
                           <a href="http://www.oxfordjournals.org/our_journals/jnci/contact_us.html" rel=""
                              title="Contact Us">Contact Us</a>
                           
                        </li>
                        <li>
                           <a href="http://www.oxfordjournals.org/access_purchase/rights_permissions.html"
                              rel=""
                              title="Rights &amp; Permissions">Rights &amp; Permissions</a>
                           
                        </li>
                        <li>
                           <a href="HTTP://www.oxfordjournals.org/access_purchase/dispatch_dates.html#JNCI.JP"
                              rel=""
                              title="Dispatch date of next issue">Dispatch date of next issue</a>
                           
                        </li>
                        <li>
                           <a href="http://publicationethics.org/" rel=""
                              title="This journal is a member of the Committee on Publication Ethics (COPE)">This journal is a member of the Committee on Publication Ethics (COPE)</a>
                           
                        </li>
                        <li>
                           <a href="http://www.oxfordjournals.org/mobile_faqs.html" rel=""
                              title="We are mobile – find out more">We are mobile – find out more</a>
                           
                        </li>
                        <li>
                           <a href="http://medicine-and-health-careernetwork.oxfordjournals.org/jobseeker/search/results/?t730=&amp;t732=469986&amp;t731=&amp;t733=&amp;t735=&amp;t737=&amp;max=25&amp;site_id=20102"
                              rel=""
                              title="Journals Career Network">Journals Career Network</a>
                           
                        </li>
                     </ul>
                     
                     <p>
                        <a href="http://www.oxfordjournals.org/our_journals/jnci/episodes_2012.html">
                           <img alt="Podcast Logo" style="float:left"
                                src="http://www.oxfordjournals.org/podcasts/podcast_icon_35x35.gif" />JNCI Podcast</a>
                        <br />
                        <br />
                        
                     </p>
                     
                  </div>
                  
                  <div class="feature separator_after">
                     
                     <h3>Connect with us!</h3>
                     <a href="https://twitter.com/JNCI_Now">
                        <img class="small_margin" alt="Connect with us on Twitter!"
                             src="http://www.oxfordjournals.org/our_journals/phisci/connect_twitter.png"
                             style="vertical-align: top; float: left; " />
                        </a>
                     <a href="https://www.facebook.com/thejnci">
                        <img class="small_margin" alt="Connect with us on Facebook!"
                             src="http://www.oxfordjournals.org/our_journals/phisci/facebook.png"
                             style="vertical-align: top; float: left; " />
                        </a>
                     
                     <p>
                        <br />
                        <br />
                        
                     </p>
                     
                  </div>
                  
                  <div class="feature separator_after">
                     
                     <h3>Editor-in-Chief</h3>
                     
                     <p>Carmen J. Allegra</p>
                     
                     <ul class="emphasised">
                        <li>
                           <a href="http://www.oxfordjournals.org/our_journals/jnci/editorial_board.html"
                              rel=""
                              title="View full editorial board">View full editorial board</a>
                           
                        </li>
                     </ul>
                     
                  </div>
                  
                  <div class="feature separator_after">
                     
                     <h3>Impact factor: 12.583</h3>
                     
                     <h3 class="five_year">5-Yr impact factor: 13.584</h3>
                     
                  </div>
                  
                  <div class="feature">
                     
                     <h3>For the Media</h3>
                     
                     <ul class="emphasised">
                        <li>
                           <a href="http://www.oxfordjournals.org/our_journals/jnci/press_room.html" rel=""
                              title="JNCI PRESS ROOM">JNCI PRESS ROOM</a>
                           
                        </li>
                     </ul>
                     
                  </div>
                  
                  <div class="feature">
                     
                     <h2 id="for_authors" title="For Authors"><span>For Authors</span></h2>
                     
                     <ul class="emphasised">
                        <li>
                           <a href="http://www.oxfordjournals.org/our_journals/jnci/for_authors/index.html"
                              rel=""
                              title="Instructions to authors">Instructions to authors</a>
                           
                        </li>
                        <li>
                           <a href="http://www.oxfordjournals.org/access_purchase/self-archiving_policyb.html"
                              rel=""
                              title="Self Archiving/Public Access Policy">Self Archiving/Public Access Policy</a>
                           
                        </li>
                     </ul>
                     <a href="http://www.oxfordjournals.org/oxfordopen/ ">
                        <img alt="Open access options for authors - visit Oxford Open"
                             src="http://www.oxfordjournals.org/resource/image/promos/oxford_open_small.gif" />
                        </a>
                     <a href="http://www.oxfordjournals.org/oxfordopen/funder_policies/">
                        <img alt="RCUK Wellcome Trust Open Access"
                             src="http://www.oxfordjournals.org/resource/image/wellcome-trust-180x100.jpg" />
                        </a>
                     
                     <p>Open access options for authors - visit <a href="http://www.oxfordjournals.org/oxfordopen/">Oxford Open</a>
                        
                     </p>
                     <a href="http://publicaccess.nih.gov/submit_process_journals.htm">
                        <img alt="PMC Logo" src="http://www.oxfordjournals.org/resource/image/pmc-logo.gif" />
                        </a>
                     
                     <ul class="emphasised">
                        <li>
                           <a href="http://publicaccess.nih.gov/submit_process_journals.htm" rel=""
                              title="This journal enables compliance with the NIH Public Access Policy">This journal enables compliance with the NIH Public Access Policy</a>
                           
                        </li>
                     </ul>
                     
                  </div>
                  
                  <div class="feature">
                     
                     <h2 id="alerting_services" title="Alerting Services"><span>Alerting Services</span></h2>
                     
                     <ul class="emphasised">
                        <li>
                           <a href="/cgi/alerts/etoc" rel="" title="Email table of contents">Email table of contents</a>
                           
                        </li>
                        <li>
                           <a href="/cgi/alerts/etoc" rel="" title="Email Advance Access">Email Advance Access</a>
                           
                        </li>
                        <li>
                           <a href="http://jnci.oxfordjournals.org/help/citetrack/index.dtl" rel=""
                              title="CiteTrack">CiteTrack</a>
                           
                        </li>
                        <li>
                           <a href="/rss" rel="" title="XML RSS feed">XML RSS feed</a>
                           
                        </li>
                     </ul>
                     
                  </div>
                  
                  <div class="feature">
                     
                     <h2 id="corporate_services" title="Corporate Services"><span>Corporate Services</span></h2>
                     
                     <ul class="emphasised">
                        <li>
                           <a href="http://www.oxfordjournals.org/corporate_services/advertising.html" rel=""
                              title="Advertising sales">Advertising sales</a>
                           
                        </li>
                        <li>
                           <a href="http://www.oxfordjournals.org/corporate_services/reprints.html" rel=""
                              title="Reprints">Reprints</a>
                           
                        </li>
                        <li>
                           <a href="http://www.oxfordjournals.org/corporate_services/classifiedadinprint.html"
                              rel=""
                              title="Classified Advertising">Classified Advertising</a>
                           
                        </li>
                     </ul>
                     
                  </div>
                  
               </div>
               <script type="text/javascript">var taxonomies = ["MED00300"];</script>
               </div>
            
            <div class="most-links-box js-marker">
               
               <div class="most-header">
                  
                  <h3>Most</h3>
                  
               </div>
               
               <ul>
                  <li class="most-cur-sel">
                     <h4>Most Read</h4>
                     	  
                     <div class="most-list">
                        	    
                        <ol>
                           <li class="first-item"><a href="http://jnci.oxfordjournals.org/cgi/content/short/92/6/443?rss=1&amp;ssource=mfr">Breast Density and Cancer Risk: What Is the Relationship?</a></li>
                           <li><a href="http://jnci.oxfordjournals.org/cgi/content/short/90/9/713?rss=1&amp;ssource=mfr">The Female Prostate</a></li>
                           <li><a href="http://jnci.oxfordjournals.org/cgi/content/short/91/14/1194?rss=1&amp;ssource=mfr">Tobacco Smoke Carcinogens and Lung Cancer</a></li>
                           <li><a href="http://jnci.oxfordjournals.org/cgi/content/short/107/6/djv048?rss=1&amp;ssource=mfr">Annual Report to the Nation on the Status of Cancer, 1975-2011, Featuring Incidence of Breast Cancer Subtypes by Race/Ethnicity,
                                 Poverty, and State</a></li>
                           <li class="last-item"><a href="http://jnci.oxfordjournals.org/cgi/content/short/105/23/1799?rss=1&amp;ssource=mfr">Elevated Plasma Vitamin B12 Levels as a Marker for Cancer: A Population-Based Cohort Study</a></li>
                        </ol>
                        	    <a href="http://jnci.oxfordjournals.org/reports/mfr1.dtl" class="view-all">» View all Most Read articles</a>
                        	  
                     </div>
                     	
                  </li>
                  <li>
                     <h4>Most Cited</h4>
                     	
                     <div class="most-list">
                        	  
                        <ol>
                           <li class="first-item"><a href="http://jnci.oxfordjournals.org/cgi/content/short/92/3/205?rss=1&amp;ssource=mfc">New Guidelines to Evaluate the Response to Treatment in Solid Tumors</a></li>
                           <li><a href="http://jnci.oxfordjournals.org/cgi/content/short/90/18/1371?rss=1&amp;ssource=mfc">Tamoxifen for Prevention of Breast Cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study</a></li>
                           <li><a href="http://jnci.oxfordjournals.org/cgi/content/short/85/5/365?rss=1&amp;ssource=mfc">The European Organization for Research and Treatment of Cancer QLQ-C30: A Quality-of-Life Instrument for Use in International
                                 Clinical Trials in Oncology</a></li>
                           <li><a href="http://jnci.oxfordjournals.org/cgi/content/short/82/13/1107?rss=1&amp;ssource=mfc">New Colorimetric Cytotoxicity Assay for Anticancer-Drug Screening</a></li>
                           <li class="last-item"><a href="http://jnci.oxfordjournals.org/cgi/content/short/82/1/4?rss=1&amp;ssource=mfc">What Is the Evidence That Tumors Are Angiogenesis Dependent?</a></li>
                        </ol>
                        	  <a href="http://jnci.oxfordjournals.org/reports/mfc1.dtl" class="view-all">» View all Most Cited articles</a>
                        	
                     </div>
                     
                  </li>
               </ul>
               
            </div>
            
            
            
         </div>
         
         
         
         <div id="oas_bottom" class="ad_hidden">
            <iframe id="id_advertframe_bottom"
                    src="/resource/htmlfiles/advert.html?p=Bottom&amp;u=jnci.oxfordjournals.org/content/101/4/256.full"
                    width="0"
                    height="0"
                    frameborder="0"
                    scrolling="no"
                    class="resize_ad"></iframe>
            
         </div>
         
         
         
         
         
         
         <div id="secondary_footer">
            
            <div id="issn">Online ISSN 1460-2105 - Print ISSN 0027-8874</div>
            
            
            <div id="copyright"><a href="http://www.oxfordjournals.org/our_journals/terms.html">Copyright ©</a> 
               <span>2015</span> Oxford University Press
               
            </div>
            
         </div>
         
         <div id="primary_footer">
            
            <div id="site_logo">
               <strong><span>Oxford Journals</span></strong>
               <em><span>Oxford University Press</span></em>
               
            </div>
            
            
            <div id="third_nav">
               
               <ul>
                  <li><a href="http://www.oxfordjournals.org/site_map.html">Site Map</a></li>
                  <li><a href="http://www.oxfordjournals.org/legal/privacy_policy.html">Privacy Policy</a></li>
                  <li><a href="http://global.oup.com/cookiepolicy/?siteid=journals">Cookie Policy</a></li>
                  <li><a href="http://www.oxfordjournals.org/legal/legal_notices.html">Legal Notices</a></li>
                  <li><a href="http://www.oxfordjournals.org/faq/">Frequently Asked Questions</a></li>
               </ul>
               
            </div>
            
            
            <div id="other_oup_sites">
               
               <form action="http://www.oxfordjournals.org/service/redirect">
                  <div>
                     <label for="site_list">Other Oxford University Press sites:</label>
                     <select name="url" id="site_list">
                        <option value="http://www.oup.com">Oxford University Press</option>
                        <option value="http://www.oxfordjournals.org/china/">Oxford Journals China</option>
                        <option value="http://www.oxfordjournals.org/japan/">Oxford Journals Japan</option>
                        <option value="http://www.oup.com/uk/academic">Academic &amp; Professional books</option>
                        <option value="http://www.oup.com/oxed">Children's &amp; Schools Books</option>
                        <option value="http://www.oup.com/uk/dictionaries">Dictionaries &amp; Reference</option>
                        <option value="http://www.oup.co.uk/newdnb/">Dictionary of National Biography</option>
                        <option value="http://www.oup.com/uk/digital_reference">Digital Reference</option>
                        <option value="http://www.oup.com/elt/">English Language Teaching</option>
                        <option value="http://www.oup.com/uk/textbooks">Higher Education Textbooks</option>
                        <option value="http://www.oup.co.uk/ieu/">International Education Unit</option>
                        <option value="http://www.oup.com/uk/law">Law</option>
                        <option value="http://www.oup.com/uk/medicine">Medicine</option>
                        <option value="http://www.oup.com/uk/music">Music</option>
                        <option value="http://www.oup.com/online">Online Products &amp; Publishing</option>
                        <option value="http://oxfordbibliographiesonline.com">Oxford Bibliographies Online</option>
                        <option value="http://oxforddictionaries.com">Oxford Dictionaries Online</option>
                        <option value="http://www.oed.com">Oxford English Dictionary</option>
                        <option value="http://www.oxfordlanguagedictionaries.com">Oxford Language Dictionaries Online</option>
                        <option value="http://www.oxfordscholarship.com">Oxford Scholarship Online</option>
                        <option value="http://www.oup.com/uk/reference">Reference</option>
                        <option value="http://www.oup.com/uk/rights">Rights and Permissions</option>
                        <option value="http://www.oup.com/uk/booksellers">Resources for Retailers &amp; Wholesalers</option>
                        <option value="http://www.oup.com/uk/corporate">Resources for the Healthcare Industry</option>
                        <option value="http://www.oup.com/vsi">Very Short Introductions</option>
                        <option value="http://www.oup.com/worldsclassics">World's Classics</option></select>
                     
                     <input type="image" src="/resource/image/buttons/go.gif" alt="Go"
                            class="inline_button" />
                     
                  </div>
               </form>
               
            </div>
            
         </div>
         <script type="text/javascript"
                 src="http://gab.cookie.oup.com/aws-cookie/oup.cookiepolicy.pack.js"
                 defer="defer"></script>
         
         <script defer="defer"
                 src="http://oi-underbar.ifactory.com/underbar/js/jquery-ui.min.js"
                 type="text/javascript"></script>
         <script defer="defer"
                 src="http://oi-underbar.ifactory.com/underbar/js/jcarousellite.js"
                 type="text/javascript"></script>
         <script defer="defer"
                 src="http://oi-underbar.ifactory.com/underbar/js/pf_oiunderbarinit.js"
                 type="text/javascript"></script>
         <script defer="defer" src="/resource/js/underbar_local.js" type="text/javascript"></script>
         <script defer="defer" type="text/javascript">
    function fnc_onDomLoaded() {
        var query_context = getQueryContext();
        PF_initOIUnderbar(query_context,":QS:default","","JRN"); 
        PF_insertOIUnderbar(0);
    };
    if (window.addEventListener) { 
        window.addEventListener('load', fnc_onDomLoaded, false); 
    } else if (window.attachEvent) { 
        window.attachEvent('onload', fnc_onDomLoaded); 
    } 
</script>
         <noscript><img src="//ouptag.scholarlyiq.com/ntpagetag.gif?js=0" height="1" width="1"
                 border="0"
                 hspace="0"
                 vspace="0"
                 alt="" /></noscript><script type="text/javascript" src="//ouptag.scholarlyiq.com/ntpagetag.js"></script><script type="text/javascript">
        var gaJsHost = (("https:" == document.location.protocol) ? "https://ssl." : "http://www.");
        document.write(unescape("%3Cscript src='" + gaJsHost + "google-analytics.com/ga.js' type='text/javascript'%3E%3C/script%3E"));
        </script><script type="text/javascript">
        try {
        var pageTracker = _gat._getTracker("UA-189672-16");
        pageTracker._setDomainName(".oxfordjournals.org");
        pageTracker._trackPageview();
        } catch(err) {}
        </script></div>
   </body>
</html>